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Glossary
angiogenesis the formation of new blood vessels, a process controlled by chem-
icals produced in the body that stimulate blood vessels or form
new ones. Angiogenesis plays an important role in the growth and
spread of cancer. Angiogenesis also occurs in the healthy body for
healing of wounds and restoring blood flow to tissues after injury.
antagonistic referring to any combination of 2 or more drugs, which results in
a therapeutic effect that is less than the sum of each drug’s effect.
antigenic having the properties of an antigen.
antigen any substance capable of inducing a specific immune response and
of reacting with the products of that response, i.e., with specific
antibody or specifically sensitized T lymphocytes, or both.
apoptosis a pattern of cell death affecting single cells, marked by shrinkage of
the cell, condensation of chromatin, and fragmentation of the cell
into membrane-bound bodies that are eliminated by phagocytosis.
Often used synonymously with programmed cell death.
cancer any disorder of cell growth that results in invasion and destruction
of surrounding healthy tissue by abnormal cells. Cancer cells arise
from normal cells whose nature is permanently changed. They
multiply more rapidly than healthy body cells and do not seem
subject to normal control by nerves and hormones. They may
spread via the bloodstream or lymphatic system to other parts of
the body, where they produce further tissue damage(metastases).
carcinogenesis the origin, production, or development of cancer, including carci-
nomas and other malignant neoplasms.
CD4+T cell an immunologically important white cell that is responsible for
cell-mediated immunity. It is the cell invaded by the human im-
munodeficiency virus and in which the virus replicates itself.
iv
Glossary v
CD8 a type I transmembrane protein found on suppressor (cytotoxic)
T cells, some natural killer cells, and most thymocytes that is
involved in T-cell antigen recognition; expressed in some T-cell
lymphomas and large granular lymphocyte leukemias.
cell cycle the periodic biochemical and structural events occurring during
proliferation of cells such as in tissue culture; the cycle is divided
into phases called G0, Gap1 (G1), synthesis (S1), Gap2 (G2), and
mitosis (M). The period runs from one division to the next.
chemokines chemotactic CYTOKINES, a family of about 50 structurally-
related heparin-binding proteins that can induce activation and
migration of specific types of white cell, attracting them to sites
of inflammation by chemotaxis. They have a fundamental role in
inflammation and are concerned in the immune system protective
responses to infecting organisms. Chemokines are also concerned
in ANGIOGENESIS. Chemokines are implicated in allergic rhini-
tis, rheumatoid arthritis, asthma, atherosclerosis, inflammatory
bowel disease, COPD, insulin resistance, obesity-induced diabetes,
multiple sclerosis and psoriasis. Chemokine-receptor antagonists
are under active investigation.
chemotherapy treatment of disease by means of chemical substances or drugs;
usually used in reference to neoplastic disease.
congenital existing at, and usually before, birth; referring to conditions that
are present at birth, regardless of their causation.
cytotoxic detrimental or destructive to cells.
cytomegalovirus any of a group of herpesviruses that attack and enlarge epithelial
cells. Such viruses also cause a disease of infants characterized by
circulatory dysfunction and microcephaly.
cytokines a general term for a range of proteins of low molecular weight that
exert a stimulating or inhibiting influence on the proliferation, dif-
ferentiation and function of cells of the immune system. Cytokines
include interleukins and interferons.
Glossary vi
EBV abbreviation for Epstein-Barr virus. A herpesvirus of the genus
Lymphocryptovirus, one of the etiologic agents of infectious
mononucleosis. It has been isolated from cells cultured from
Burkitt’s lymphoma and has been found in certain cases of na-
sopharyngeal carcinoma. There may be an association between
EBV and chronic fatigue syndrome. High titers of EBV are present
in some tumors, but a causative role has not been proven. Called
also EB virus.
endotoxin a toxin contained in the cell walls of some microorganisms, espe-
cially gram-negative bacteria, that is released when the bacterium
dies and is broken down in the body. Fever, chills, shock, leukope-
nia, and a variety of other symptoms result, depending on the
particular organism and the condition of the infected person.
epigenetic relating to inheritable changes in the pattern of gene expression
caused by factors other than changes in the nucleotide sequence of
genes. It is now recognized that cancer is caused both by genetic
and epigenetic changes and that these two factors are intimately
interrelated in the development of tumours.
erythrocyte red blood cell; corpuscle; one of the formed elements in peripheral
blood. Normally, in humans, the mature form is a non-nucleated,
yellowish, biconcave disk, containing hemoglobin and transporting
oxygen.
erythropoiesis red blood cell production that occurs in bone marrow and involves
maturation of nucleated precursors into erythrocytes regulated by
the hormone erythropoietin produced in the kidneys.
erythropoietin a glycoprotein hormone synthesized mainly in the kidneys and
released into the bloodstream in response to anoxia. The hormone
acts to stimulate and to regulate the production of erythrocytes
and thus increases the oxygen-carrying capacity of the blood.
growth factor hematopoietic growth factor (HGF), any of several glycoproteins
that regulate the survival, self-renewal, proliferation, and differen-
tiation of hematopoietic progenitor cells. There are two nomen-
clature groups: interleukins (IL) and colony-stimulating factors
(CSF).
helminths species the word ‘helminth’ is a general term meaning ‘worm’, but there
are many different types of worms. Prefixes are therefore used
to designate types: platy-helminths for flat-worms and nemat-
helminths for round-worms.
Glossary vii
hematopoiesis the normal formation and development of blood cells in the bone
marrow.
herpesvirus any of a family of DNA viruses that form characteristic inclusion
bodies within the nuclei of host cells and cause diseases such as
chickenpox, infectious mononucleosis, herpes simplex, and shin-
gles.
homeostasis the principle of self-regulating information feedback by which con-
stant conditions are maintained in a biological system such as the
human body. Homeostasis is essential to life and applies to thou-
sands of bodily parameters. Some of the more obvious examples
are temperature regulation, blood acidity control, blood pressure
control, heart rate, blood sugar levels and hormone secretion.
hormesis the stimulating effect of subinhibitory concentrations of any toxic
substance on any organism.
humoral pertaining to or derived from a body fluid. The humoral part of
the immune system includes antibodies and immunoglobulins in
blood serum.
IFN−β interferon-beta, an interferon produced by fibroblasts in response
to viruses or foreign nucleic acids.
immune response the reaction of the body to foreign or potentially dangerous sub-
stances (antigens), particularly disease-producing microorganisms.
immunodeficiency a condition resulting from a defective immune mechanism; may
be primary (due to a defect in the immune mechanism itself) or
secondary (dependent on another disease process).
immunosenescence the age-associated decline of the immune system and host defense
mechanisms. Elderly individuals frequently have a decline in cell-
mediated immunity and secondary declines in humoral immunity.
immunosuppression prevention or interference with the development of immunologic
response; may reflect natural immunologic unresponsiveness (tol-
erance), may be artificially induced by chemical, biologic, or phys-
ical agents, or may be caused by disease.
immunosuppressive pertaining to a substance or procedure that lessens or prevents an
immune response.
immunosurveillance theory positing that the immune system eliminates aberrant or
tumor cells that arise spontaneously.
Glossary viii
immunotherapy treatment of disease by inducing, enhancing, or suppressing an
immune response.
leukopoiesis the production of white blood cells. Monocytes, neutrophils,
basophils, and eosinophils are produced from bone marrow
myeloblasts. Lymphocytes develop from lymphoblastic precursors
in peripheral lymphoid tissue.
lymphocyte a family of mononuclear, nonphagocytic white blood cells that
circulate in blood, lymph, and peripheral lymphatic tissues. Lym-
phocytes are categorized as B and T lymphocytes and natural
killer cells and are responsible for humoral and cellular immunity
and tumor surveillance.
macrophages white blood cells (activated monocytes) that protect the body
against infection and foreign substances by breaking them down
into antigenic peptides recognized by circulating T cells.
malignant (of a tumor) characterized by uncontrolled growth; cancerous, in-
vasive, or metastatic.
MHC major histocompatibility complex. A small region of the genome
that is highly conserved in vertebrate evolution, which encodes
three classes of polymorphic molecules known as the immune
recognition unit. The MHC is located on the short arm of chromo-
some 6 in humans, and on chromosome 17 in mice. The products
of the MHC gene complex are membrane-bound receptors for anti-
gens and peptides which, when bound, are displayed to T cells; if
the bound peptides are recognised by the T cells, an immune re-
sponse against those peptides is initiated.
multipotent of stem cells, having the ability to differentiate into several types
of specialized cells.
myelogenous pertaining to the cells produced in bone marrow or the tissue from
which such cells originate.
myeloproliferative relating to excess proliferation of hematopoietic stem cells, chiefly
in the bone marrow, as in chronic myelogenous leukemia and poly-
cythemia vera.
natural killer cell a lymphocyte that is activated by double-stranded RNA or lym-
phokines and fights off viral infections and tumors without evident
antigenic specificity.
neutropenia abnormal decrease in the neutrophil count associated with acute
leukemia, chemotherapy, and idiosyncratic drug reactions, predis-
posing individuals to infection.
Glossary ix
oncogenic pertaining to the origin and development of tumors or cancer.
p02 the concentration of oxygen in the blood. this commonly measured
parameter is an important indicator of the efficiency with which
oxygen is transferred from atmosphere to blood. when p02 drops,
respiration is automatically stimulated.
pathogen any disease-producing agent or microorganism.
phenotype the observable features of an individual organism that result from
an interaction between the genotype and the environment in which
development occurs. the interaction is that between nature and
nurture. variations due to nature are the inherited aspects of the
organism, the genotype, while nurture denotes the (usually not
inherited) effects of the environment upon the organism.
platelets blood platelets or thrombocytes, consisting of non-nucleated cy-
toplasmic fragments of large bone-marrow cells 3 µm in diameter
called megakaryocytes that have entered the blood circulatory sys-
tem. platelets play an important part in blood clotting.
pluripotent relating to or being a cell that is capable of differentiating into
cells of any type of tissue except placental tissue.
premalignant pertaining to any lesion that is interpreted as precancer.
proliferate to grow or multiply by rapidly producing new tissue, parts, cells,
or offspring.
quiescent at rest; latent; the G0 stage of the cell cycle.
radiotherapy the treatment of neoplastic disease by using x-rays or gamma rays
to deter the proliferation of malignant cells by decreasing the rate
of mitosis or impairing DNA synthesis.
rhinovirus any of several strains of enterovirus that cause respiratory tract
infections, including the common cold.
rotavirus any of a genus of wheel-shaped reoviruses, including one that
causes gastroenteritis, especially in infants and newborn animals.
sporadic (of a number of events) occurring at scattered, intermittent, and
apparently random intervals.
stem cell a cell that is not differentiated itself but can undergo unlimited
division to form other cells, which either remain as stem cells or
differentiate to form specialized cells.
Glossary x
T cell a lymphocyte that participates in cellular immunity, including cell-
to-cell communication. The major T cell categories are T-helper
and T-suppressor cytotoxic cell.
TGF-β transforming growth factor beta; a growth factor synthesized by
skeletal cells; found in most species.
Th1 T Helper Cell Type 1.
Th2 T Helper Cell Type 2.
Th17 T helper 17 cells are a subset of T helper cells producing inter-
leukin 17 (IL-17) discovered in 2007. They are considered develop-
mentally distinct from Th1 and Th2 cells and excessive amounts of
the cell are thought to play a key role in autoimmune disease such
as multiple sclerosis (which was previously thought to be caused
by Th1 cells), but also psoriasis, autoimmune uveitis, juvenile di-
abetes, rheumatoid arthritis, and Crohn’s disease.
thrombocytopenia an abnormally low level of platelets in the circulating blood.
transient pertaining to a condition that is temporary or of short duration,
usually not recurring.
Treg regulatory T cells.
tumor a new growth of tissue in which cell multiplication is uncontrolled
and progressive. Tumors are also called neoplasms, which means
that they are composed of new and actively growing tissue. Their
growth is faster than that of normal tissue, continuing after cessa-
tion of the stimuli that evoked the growth, and serving no useful
physiologic purpose.
Chapter 1
General Introduction
This thesis deals with several aspects of mathematical modeling and analysis in cel-
lular dynamics. The work fits into the general framework of the study of population
dynamics. The population particularly considered in this work is composed of a large
amount of cells with both cases of healthy and cancerous cells being investigated. The
mathematical framework used in this study relies heavily upon the theory of differential
equations. More precisely, the type of differential equations used in order to develop
models during this thesis project varies from ordinary differential equations (ODE)
to delayed differential equations (DDE) which in turn were actually the result of the
method of characteristics being applied on a couple of systems of partial differential
equations (PDE).
The first model proposed in this thesis yielded a DDE that featured a distributed
delay as well as constant one. A detailed stability analysis of the resulting DDE system
was performed with a focus on the analysis of the behavior of the steady states. The
trivial steady state, describing cells dying out, was proven to be globally asymptoti-
cally stable when it is the only equilibrium of the system using a constructed Lyapunov
function. The asymptotic stability of the positive steady state, the most biologically
meaningful one, was analyzed using the characteristic equation.
The second model of this thesis resulted in a system of differential equations with
a state-dependent delay for which we investigated the existence and stability of the
steady states. A sufficient condition for the global asymptotic stability of the trivial
steady state was obtained using a Lyapunov-Razumikhin function. The analysis of the
positive steady state behavior concluded on the existence of a Hopf bifurcation.
The third and final model proposed in this thesis consists of a system of ODEs
that led to highlight the importance of the results yielded by a simple mathematical
model in helping to improve our understanding of the complex interactions between
the immune system and cancerous cells. The study of the latter model centered on
the influence of infections on cancer risk and more precisely the interference of such
infections with the immune responses against cancer.
1
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Motivation
The role of cellular dynamics in cancer prevention and cancer therapies development
has become more prominent in the recent decades. Especially the role of Stem Cells
dynamics [26, 44].
Stem cells are undifferentiated cells that have the unique capabilities of differen-
tiation into multiple types of specialized cells and unlimited capacities of self-renewal
[117]. The earliest and most intensively studied models of lineage-committed stem cells
are Hematopoietic Stem Cells (HSCs). In the early 1960s, Till and McCulloch [112]
found the first genetic evidence for the existence of HSCs. Ever since, a great deal of
models have been proposed either describing normal HSCs dynamics [8, 43], or blood
cell diseases like cyclical neutropenia [22, 61], thrombocytopenia [101, 109] or chronic
myelogenous leukemia [11, 95] (normal HSCs dynamics are the main focus of the first
part of this thesis).
Despite the fact that HSCs dynamics have been intensively studied for several
decades, many open questions remain unanswered, due to the difficulty to obtain ex-
perimental measurements of some of the mechanisms involved in the hematopoiesis
process as well as the complexity of the process itself.
In recent years, there is an increasing amount of evidence suggesting that cancer
is originated and sustained by a small subset of the population of cells called Cancer
Stem Cells (CSCs) [53]. A cancer stem cell is a cell type within a tumor that possesses
the capacity of self-renewal and can give rise to the heterogeneous lineages of cancer
cells [38]. CSCs also possess features that enables them to elude the immune system
recognition [30] which renders them virtually invisible to the immune response (This
particular point is the main focus of the second part of the thesis).
Cancer stem cells have been successfully identified in acute myelogenous leukemia
[35, 40], breast cancer [15], brain tumors [63, 74, 107], and pancreas cancer [50].
As the field of stem cell research continues to expand, we do hope to contribute, by
the present work, to the understanding of normal stem cell behavior as well as some
abnormalities that may sometimes arise in stem cell dynamics.
1.1 Hematopoietic Stem Cells
Hematopoietic Stem Cells (HSCs) are the multipotent stem cells, located in the bone
marrow, from which originates all differentiated blood cell lineages (red blood cells,
white cells and platelets) through the process of hematopoiesis.
Due to the large number of divisions, and the amount of cells and cytokines involved
in hematopoiesis, numerous issues may arise at different cellular levels and sometimes
lead to disorders affecting blood cells. Among a wide variety of disorders affecting
blood cells, myeloproliferative diseases are of great interest. They are characterized by
a set of conditions that cause blood cells to grow abnormally. They include chronic
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myelogenous leukemia, a cancer of the white blood cells that exhibits, in some cases,
periodic oscillations in all blood cell counts (see [96]). Myeloproliferative disorders
usually originate from the HSC population: an uncontrolled proliferation of HSCs can
upset the entire physiological process and result in a much faster or slower proliferation
(i.e., the influence of cell cycle duration which is the main focus of Chapter 3).
A low blood cell counts can be associated with many diseases and disorders that cause
the body to have fewer blood cells than usual. It can be associated to a bone marrow
failure resulting from a disease affecting another organ (liver or kidney, for instance),
or to a side affect of a specific treatment (chemotherapy drugs, for instance).
The process of hematopoiesis comprises of multiple complex mechanisms regulated
by a wide range of hormone-like molecules called growth factors that respond to stimuli
and enable a balance between differentiation, self-renewal and cell mortality (The main
focus of Chapter 2). For instance, in case of a deficiency of oxygen in the blood, mature
red blood cells trigger the release of erythropoietin from the kidneys which inhibits
apoptosis during hematopoiesis, leading to an increase in red blood cells production
[71].
1.1.1 HSC dynamics : Mathematical modeling
Mathematical modeling of HSC dynamics has been the focus of a large panel of re-
searchers over the last four decades, with attempts to improve the understanding of
the complex mechanisms regulating HSC functions, throughout the course of normal
and pathological hematopoiesis. One of the earliest mathematical models that shed
some light on this process was proposed by Mackey [76] in 1978 inspired by the work
of Lajtha [73], and Burns and Tannock [31]. Mackey’s model consists of a system of
two delay differential equations describing the evolution of the HSC population divided
into proliferating and quiescent cells (also called resting cells). This model has been
studied, analyzed and applied to hematological diseases by many authors (see, for in-
stance, [9, 95, 96, 99]). For many years, only systems with discrete delay were proposed
to describe HSC dynamics see, for example, [8, 77, 78]. Then, more recently, Adimy
and Crauste [3], Adimy, Crauste, and Ruan [9], and Bernard, Bélair, and Mackey [21]
proposed and analyzed modified versions of Mackey’s model [76] by considering a dis-
tribution of cell cycle durations. In 2005, Adimy and Crauste [4] and Adimy, Crauste,
and Pujo-Menjouet [12] proposed a model of HSC dynamics in which the cell cycle
duration depends upon the cell maturity.
Mathematical models describing the action of growth factors on the hematopoiesis
process have been proposed by Bélair et al in 1995 [18], and Mahaffy et al in 1998
[81]. They considered an age-structured model of HSC dynamics, coupled with a dif-
ferential equation to describe the action of a growth factor on the reintroduction rate
from the resting phase to the proliferating one. In 2006, Adimy et al [10] proposed
a system of three delay differential equations describing the production of blood cells
under the action of growth factors assumed to act on the rate of reintroduction into
the proliferating phase. Adimy and Crauste considered and analyzed two models of
hematopoiesis dynamics with: the influence of growth factors on HSC apoptosis [5],
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and the action of growth factors on the apoptosis rate as well as on the reintroduction
rate into the proliferating phase [6].
Many of the aforementioned mathematical models have subsequent implications to
cancer prevention, development and treatment.
1.1.2 Our contribution to HSC dynamics modeling
The originality of our study regarding the influence of growth factors concentrations on
differentiation, proliferation rate and apoptosis lays in the proposed model itself which,
to our knowledge, has never been considered in hematopoiesis dynamics beforehand.
Regarding the originality of our study relating to the influence of the total popula-
tion of quiescent cells on the cell cycle duration, it lays in the refinement of the model
proposed by Adimy et al. [13].
1.2 Immunosenescence, Cancer and Stem Cells
The immune system is not permanently fully efficient. Indeed, immunosenescence is
a process that reflects a gradual decrease of immune system activity with age mainly
through a decreased capacity of immunosurveillance [49]. The beginning of immunose-
nescence is assumed to be associated with the beginning of thymopoiesis decline. In-
deed, the thymus play a crucial role in the development of T cells but also in main-
taining immune efficiency [102]. Maximal activity is reached at puberty (from 10 to 19
years old according to the World Health Organization) and decrease progressively in
adults [108]. The elderly (more than 65 years old (WHO)) usually have i) a depleted
population of naive T cells (the set of T lymphocytes that can respond to novel anti-
gens) [92, 93], ii) a shrinking repertoire of T cell clones [55, 83, 93], iii) an increased
number of naturally occurring regulatory T cells that down-regulate T cell responses
[46, 98], iv) a low grade, pro-inflammatory status [92], and v) increased numbers of
myeloid-derived suppressor cells, which are associated with impaired T-cell functioning
and produce high amounts of reactive oxygen species [24]. All these immune-associated
changes can potentially promote tumor proliferation [55].
1.2.1 The Link Between Aging and Cancer : Mathematical modeling
Mathematical models have been used, since 1954, to investigate the link between aging
and cancer by correlating increasing incidences of cancer with advancing age to muta-
tion accumulation [16]. More recently, genetic and epigenetic changes in stem cells have
been associated with both normal aging processes and cancer risk [23, 36, 106, 111].
Normal aging is linked with lymphocytes immunosenescence leading to increased se-
cretion of cytokines such as IL− 6 and TNF − α [90]. This state of chronic immune
activation has been associated with DNA-modifying events that lead to an increased
risk of malignancy [28]. Inflammatory cytokines are also important regulators of stem
cell states [70]. Mathematical models have proven useful in the study the effects of
stress and hormesis [86] on lifespan and the relationship between accelerated aging
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and carcinogenesis [32–34]. Stochastic models have been used to study the balance
between damaged and repaired states in stressed worms. Predictions of lifespan us-
ing this model matched the experimental observations [33]. Further stochastic models
have been used to examine levels of free radicals and cumulative damage to DNA, lipid
structures, and proteins, leading to genetic instability and malignant transformation
[32]. Predictions from these models matched both experimental data of survival and
fertility curves in Mediterranean fruit flies, and cancer incidence in rats exposed to
bromode-oxyuridine [33, 34].
1.2.2 Our contribution to the modeling of the interactions between aging
and cancer
The originality of our study lays in the ability of our model to predict that acute
immunosuppressive infections could also impact cancer risk and in a larger extent
than persistent infections. Empirical evidences of such situation are obviously harder
to identify, but the impact of “common” diseases on immune system and their relation
with cancer risk are worthy of investigation. Our results suggest a stronger impact of
acute and repeated immune challenges after the beginning of immunosencence.
Organization of the thesis
The thesis is structured in two parts besides this introductory chapter. The first
part consists of two chapters dedicated to mathematical modeling and analysis of
hematopoietic stem cell dynamics.
In chapter 2, we propose and analyze the following age-structured partial differen-
tial model for hematopoietic stem cell dynamics, in which proliferation, differentiation
and apoptosis are regulated by growth factor concentrations,
∂n
∂t
+ ∂n
∂a
= −(δ + β(E1(t)))n(t, a), a > 0,
∂p
∂t
+ ∂p
∂a
= −γ(E2(t))p(t, a), 0 < a < τ,
∂m
∂t
+ ∂m
∂a
= −µm(t, a), a > 0,
(1.2.1)
where we denote respectively by n(t, a), p(t, a) and m(t, a) the cell population densities
of quiescent HSCs, proliferating HSCs and mature cells, with age a ≥ 0 at time t ≥ 0.
The age represents the time spent by a cell in one of the three compartments. Quiescent
cells are assumed to die with a constant rate 0 ≤ δ ≤ 1, and they can be introduced
into the proliferating phase with a rate β in order to divide. We suppose that β
depends upon a growth factor concentration E1. We assume that the duration of
the proliferating phase is the same for all cells, so τ is constant, and describes an
average duration of the cell cycle. The population of proliferating cells is controlled by
apoptosis γ ≥ 0. We assume that the apoptosis rate γ depends upon the concentration
of growth factor E2. The portion of quiescent cells that differentiate to mature cells
is denoted by KN ≥ 0 which, we assume, depends upon a growth factor concentration
denoted E3, whereas the portion of daughter cells entering the mature phase is denoted
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by KP ≥ 0 which, we assume, depends upon a growth factor concentration denoted
E4.
System (1.2.1) is completed by boundary conditions (for a = 0), that describe the
flux of cells entering each phase, and by initial conditions (for t = 0). The boundary
conditions of (1.2.1) are, for t > 0,
n(t, 0) = 2αp(t, τ),
p(t, 0) = β(E1(t))N(t),
m(t, 0) = KN (E3(t))N(t) + 2KP (E4(t))p(t, τ),
(1.2.2)
where
N(t) =
∫ +∞
0
n(t, a)da, P (t) =
∫ τ
0
p(t, a)da, M(t) =
∫ +∞
0
m(t, a)da.
Initial conditions of (1.2.1) are given by nonnegative L1-functions n0, p0 and m0,
such that
n(0, a) = n0(a), m(0, a) = m0(a), for a ≥ 0,
p(0, a) = p0(a), for a ∈ [0, τ ].
(1.2.3)
The growth factor concentrations Ei(t), i = 1, 2, 3, 4, follow the evolution equations
E′i(t) = −kiEi(t) + fi(M(t)), (1.2.4)
where the coefficients ki > 0 are the degradation rates of the growth factors Ei. We as-
sume that the functionsM 7→ fi(M) are positive, decreasing and satisfy limM→+∞ fi(M) =
0.
Using the method of characteristics, we reduce the age-structured model (1.2.1)-
(1.2.2)-(1.2.3)-(1.2.4) to the following delay differential system
N ′(t) = −(δ + β(E1(t)))N(t)
+ 2αβ(E1(t− τ))N(t− τ) exp
(
−
∫ t
t−τ
γ(E2(s)) ds
)
,
M ′(t) = −µM(t) +KN (E3(t))N(t)
+ 2KP (E4(t))β(E1(t− τ))N(t− τ) exp
(
−
∫ t
t−τ
γ(E2(s)) ds
)
,
E′i(t) = −kiEi(t) + fi(M(t)).
(1.2.5)
We investigate the existence and stability of the steady states of the reduced delay
differential system. The trivial steady state, describing cell’s dying out, is proven to
be globally asymptotically stable when it is the only equilibrium of the system using
the following constructed Lyapunov functional
Vε : (C([tε, tε + τ ],R+))6 → R+, Defined by
Φ = (ϕ,ψ, χ1, χ2, χ3, χ4),
Vε(Φ) = ϕ(tε + τ) + 2α exp
(
− τγ
(f2(0)
k2
+ ε
))
×
∫ 0
−τ
β(χ1(θ + tε + τ))ϕ(θ + tε + τ) dθ.
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The composition with the solution X(t) := (N(t),M(t), Ei(t)) of equation (1.2.5)
leads, for t ≥ tε + τ , to the function
t 7→ Vε(Xt) = N(t) + 2α exp
(
− τγ
(f2(0)
k2
+ ε
)) ∫ t
t−τ
β(E1(s))N(s)ds.
The asymptotic stability of the positive steady state, the most biologically mean-
ingful one, is analyzed using the characteristic equation. This study may be helpful
in understanding the uncontrolled proliferation of blood cells in some hematological
disorders.
The work presented in Chapter 2 has been published in a peer-reviewed journal
and is reproduced in extenso.
In chapter 3, we propose and analyze a mathematical model describing the dynam-
ics of a hematopoietic stem cell population, in which the duration of the cell cycle τ
depends upon the total population of quiescent cells. The function τ : R+ → [0, τmax]
is supposed to be bounded, positive, continuously differentiable (C2) and increasing.
The method of characteristics reduces the age-structured model to a system of differ-
ential equations with a state-dependent delay. We perform a detailed stability analysis
of the following delay differential equation
x′(t) = f(xt), for t ≥ 0, (1.2.6)
where xt is defined by xt(θ) = x(t+ θ) for θ ∈ [−τmax, 0], and the function f : C → R
is given, for φ ∈ C, the space of continuous functions on [−τmax, 0], by
f(φ) = g(φ(0), φ(−τ(φ(0)))).
The function g : (R+)2 → R is given by
g(x, y) = −δx− β(x)x+ 2β(y)ye
−γτ(x)
1 + 2τ ′(x)e−γτ(x)β (y) y
, (x, y) ∈ (R+)2,
where δ > 0 and the function β is assumed to be continuously differentiable, bounded
and positive. Furthermore, we assume that β is decreasing with limx→+∞ β(x) = 0.
Afterwords, we consider the following Lyapunov-Razumikhin function
V : R+ → R+ given by V (x) = x2/2.
Where, for x ∈ R+, u(x) ≤ V (x) ≤ v(x), with u(x) = x2/2 and v(x) = x2.
We define p : R+ → R+ by p(x) = xe2ατ(
√
2x), x ∈ R+
with 0 < α < min{γ, γ − ln(2β(0)/δ)/τ0},
Then, we consider x to be a solution of (1.2.6) such that, for t ≥ 0, θ ∈ [−τmax, 0],
V (x(t+ θ)) < p (V (x(t))) .
and we obtain a sufficient condition for the global asymptotic stability of the trivial
steady state, describing cell’s dying out.
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Furthermore, it is shown that a unique non-trivial steady state can appear through
a transcritical bifurcation of the trivial steady state. The analysis of the positive steady
state’s behavior concludes to the existence of a Hopf bifurcation and gives criteria for
stability switches. Moreover, we have confirmed the analytical results by numerical
simulations.
The work presented in Chapter 3 is soon to be submitted for publication.
The second part of the thesis is comprised of a single chapter where we focus on the
interactions between the immune system and cancer cells proliferation. Particularly,
in Chapter 4, we consider the compartment of invisible cells in order to deepen our
analysis of the aforementioned interactions. We propose the following ODE system
dH
dt
= β1H
(
1− N
K
)
− µ1H,
dP
dt
= β1P
(
1− N
K
)
+ µ1H − (µ2 + ω(t))P,
dC
dt
= β2C
(
1− N
K
)
+ µ2P − (µ3 + ω(t))C,
dI
dt
= β2I
(
1− N
K
)
+ µ3C,
where H represents healthy cells, P precancerous cells, C cancerous cells, I can-
cerous cells that are invisible to the immune system and N the total number of cells
(i.e., N = H + P + C + I). Precancerous cells become cancerous at rate µ2, and
finally invisible at rate µ3. We consider that invisible cancerous cells have acquired
the capacity to avoid destruction by immune system whatever the mechanism implied.
Healthy and precancerous cells replicate at rate β1 while cancerous and invisible cells
replicate at rate β2 (greater than β1) with a maximal total number of cells K (i.e., car-
rying capacity) in order to induce competition between different kinds of cells. Each
precancerous and cancerous cells can be eliminated from the organism through the
function ω(t).
Afterwords, we show that the frequency, the duration and the action (positive or
negative) of immune challenges may significantly impact tumor proliferation. First, we
observe that a long immunosuppressive challenge increases accumulation of cancerous
cells. However, short immune challenges result in an even greater accumulation of
cancerous cells for the same total duration of immunosuppression. Finally, we show
that short challenges of immune activation could lead to a slightly decrease in cancerous
cell accumulation compared to a long one.
The work presented in Chapter 4 has been published in a peer-reviewed journal
and is reproduced in extenso.
Part I
Hematopoietic Stem Cell
Dynamics
9
Chapter 2
Age-structured model of hematopoiesis
dynamics with growth
factor-dependent coefficients ∗
Abstract
We propose and analyze an age-structured partial differential model for hematopoietic
stem cell dynamics, in which proliferation, differentiation and apoptosis are regulated
by growth factor concentrations. By integrating the age-structured system over the
age and using the characteristics method, we reduce it to a delay differential system.
We investigate the existence and stability of the steady states of the reduced delay
differential system. By constructing a Lyapunov function, the trivial steady state,
describing cell’s dying out, is proven to be globally asymptotically stable when it is the
only equilibrium of the system. The asymptotic stability of the positive steady state,
the most biologically meaningful one, is analyzed using the characteristic equation.
This study may be helpful in understanding the uncontrolled proliferation of blood
cells in some hematological disorders.
2.1 Introduction
Hematopoiesis is the physiological process that ensures the production and regula-
tion of blood cells. It involves a pool of undifferentiated and self-renewing cells called
hematopoietic stem cells (HSCs), located in the bone marrow, from which arises all
differentiated blood cell lineages (red blood cells, white cells and platelets).
Proliferation, differentiation and apoptosis are processes occurring during hema-
topoiesis and are all mediated by a wide range of hormone-like molecules called growth
factors. The growth factors play an activator or inhibitor role in this process and they
∗M. Adimy, Y. Bourfia, M. L. Hbid, C. Marquet, Age-structured model of hematopoiesis dynamics
with growth factor-dependent coefficients, Electron. J. Diff. Equ., Vol. 2016 (2016), No. 140, pp.
1-20.
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act on every cell compartment: primitive stem cells, progenitors and precursors. Their
role to maintain homeostasis of blood cells is essential. The production of red blood
cells (erythropoiesis) and platelets (megakaryopoiesis) seems to be regulated by specific
growth factors whereas white blood cell production (leukopoiesis) is more complicated
and less clearly understood. For the red blood cells, the erythropoietin (EPO) helps to
regulate erythrocyte production (Adamson [2]). A decrease in mature red blood cell
count leads to a decrease in tissue p02 levels, which in turn increases the production
of EPO by the kidneys and controls erythropoiesis. For the platelets, it seems that
their production and regulation are controlled by feedback mechanisms involving spe-
cific cytokines such as thrombopoietin (TPO). However, it has been shown that the
cytokine TPO affects other cell lines as well (Tanimukai et al [110]), which means that
the three lines are probably not fully independent, and there is a feedback control from
mature cells to HSCs. Regulation of the multiple fates of HSCs, including quiescence,
self-renewal, differentiation and apoptosis, requires the cooperative actions of several
growth factors that bind to receptors on these cells. Many of the important players in
this regulation have been identified (Tanimukai et al [110]).
Due to the number of divisions, and the quantity of cells and cytokines involved
in hematopoiesis, issues may arise at different cellular levels and sometimes result in
disorders affecting blood cells. Among a wide variety of disorders affecting blood cells,
myeloproliferative diseases are of great interest. They are characterized by a group
of conditions that cause blood cells to grow abnormally. They include chronic myel-
ogenous leukemia, a cancer of white blood cells. In some cases, chronic myelogenous
leukemia exhibits periodic oscillations in all blood cell counts (see [96]). Myeloprolif-
erative disorders usually originate from the HSC compartment: an uncontrolled pro-
liferation in the HSC compartment can perturb the entire system and leads to a quick
or slow proliferation. A low blood counts (white cell count, red cell count, or platelet
count) can be associated with many diseases and conditions that cause the body to
have too few blood cells. It can be associated to a bone marrow failure, consecutive
to disease of another organ (for example, liver or kidney), or secondary to treatment
with some drugs (for example, chemotherapy drugs).
Mathematical modeling of hematopoiesis dynamics has been the focus of a large
panel of researchers over the last four decades, with attempts to improve the under-
standing of the complex mechanisms regulating HSC functions, throughout the course
of normal and pathological hematopoiesis. One of the earliest mathematical models
that shed some light on this process was proposed by Mackey [76] in 1978 inspired by
the work of Lajtha [73], and Burns and Tannock [31]. Mackey’s model is a system of
two delay differential equations describing the evolution of the HSC population divided
into proliferating and quiescent cells (also called resting cells). This model has been
studied, analyzed and applied to hematological diseases by many authors (see for in-
stance, [9, 77, 78, 95, 96, 99]). We refer the reader interested in this topic, in addition
to the previous articles, to the review papers by Adimy and Crauste [7], Haurie et al
[59], Mackey et al [79], and the references therein.
Mathematical models describing the action of growth factors on the hematopoiesis
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process have been proposed by Bélair et al in 1995 [18], and Mahaffy et al in 1998
[81]. They considered an age-structured model of HSC dynamics, coupled with a
differential equation to describe the action of a growth factor on the reintroduction
rate from the resting phase to the proliferating one. In 2006, Adimy et al [10] proposed
a system of three delay differential equations describing the production of blood cells
under the action of growth factors assumed to act on the rate of reintroduction into
the proliferating phase. Adimy and Crauste considered and analyzed two models of
hematopoiesis dynamics with: the influence of growth factors on HSC apoptosis [5],
and the action of growth factors on the apoptosis rate as well as on the reintroduction
rate into the proliferating phase [6].
In this paper, we consider the influence of growth factors on the apoptosis rate,
on the differentiation rates (of the proliferating and quiescent cells), as well as on the
reintroduction rate into the proliferating phase (see Figure 2.1). The resulting sys-
tem is composed by three age-structured partial differential equations for the different
compartments of cell population, coupled with a system of four differential equations
to describe the action of growth factors on different parameters of the system. To our
knowledge this model has never been considered in hematopoiesis dynamics.
The paper is organized as follows. In section 2.2, we provide some biological back-
ground leading to an age-structured partial differential model for HSC dynamics. In
section 2.3, we use the method of characteristics to reduce the model to a system of
delay differential equations. In section 2.4, we establish some proprieties of the solu-
tions such as positivity and boundedness. In section 2.5, we investigate the existence
of steady states. In section 2.6, we prove the global asymptotic stability of the trivial
steady state using a Lyapunov function. In section 2.7, we linearize the delay system
about each steady state and we deduce the delay-dependent characteristic equation.
Then, we obtain the local asymptotic stability of the positive steady state.
2.2 Age-structured partial differential model
We consider two cell populations, HSC population (in the bone marrow) and mature
blood cell population (in the bloodstream), for instance red blood cells. The HSC
population is divided into proliferating and quiescent cells. Proliferating cells are the
ones performing the cell division (growth, DNA synthesis and mitosis). Quiescent (or
resting) HSCs are actually in a quiescent phase (G0-phase). HSCs generate cells that
undergo terminal differentiation resulting in mature circulating blood cells. Mature
blood cells control the HSC population through growth factors. We denote respec-
tively by n(t, a), p(t, a) and m(t, a) the cell population densities of quiescent HSCs,
proliferating HSCs and mature cells, with age a ≥ 0 at time t ≥ 0. The age represents
the time spent by a cell in one of the three compartments. A schematic representation
of this model is given in Figure 2.1. Details of the modeling are presented hereafter.
Quiescent cells are assumed to die with a constant rate 0 ≤ δ ≤ 1, and they
can be introduced into the proliferating phase with a rate β in order to divide. We
suppose that β depends upon a growth factor concentration E1, that stimulates the
proliferative capacity of HSCs: the more growth factor, the more proliferation of HSCs.
Hence the feedback induced by the growth factor E1 is positive, and the function β
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is supposed to be increasing, with β(0) = 0. As soon as a cell enters the proliferating
phase, it is committed to divide a time τ ≥ 0 later. We assume that the duration
of the proliferating phase is the same for all cells, so τ is constant, and describes an
average duration of the cell cycle. The population of proliferating cells is controlled by
apoptosis γ ≥ 0, which is a programmed cell death that eliminates deficient cells and
also maintains the homeostatic state of cell population. We assume that the apoptosis
rate γ depends upon the concentration of growth factor E2 (for example, EPO, see
[71]). Since an increase of the growth factor concentration E2 leads to a decrease of the
apoptosis rate, we assume that γ is a decreasing function of E2 and limE2→+∞ γ(E2) =
0. The portion of quiescent cells that differentiate to mature cells is denoted byKN ≥ 0
which, we assume, depends upon a growth factor concentration denoted E3. Since an
increase of growth factor E3 leads to an increase of the differentiation, we suppose that
E3 7→ KN (E3) is an increasing function. Here, we only consider one kind of mature
cells, for instance red blood cells. Then, we can consider that 1 − (δ + β + KN ) ≥ 0,
the remainder of quiescent cells, differentiate to other cell lineages (for instance, white
blood cells and platelets). At the end of the proliferating phase, each cell divides into
two daughter cells. The daughter cells can either differentiate and enter the mature
phase or stay in HSC compartment and enter to the G0-phase. We assume that the
part of daughter cells α ≥ 0 that stay in HSC compartment is constant. This is
important because HSCs could maintain their characteristic properties of self-renewal
and lack of differentiation could provide an unlimited source of cells to maintain the
homeostasis. The portion of daughter cells entering the mature phase is denoted by
KP ≥ 0 which, we assume, depends upon a growth factor concentration denoted E4.
As for quiescent cells, we suppose that E4 7→ KP (E4) is an increasing function and
that the portion 1− (α+KP ) ≥ 0 of daughter cells differentiate to other cell lineages.
We suppose that the mature cells die with a constant rate µ ≥ 0. All the growth
factor concentrations E1, E2, E3 and E4 are controlled by the mature cells through
functions fi, i = 1, 2, 3, 4 acting as negative feedbacks of the mature blood cells on the
production of growth factors (see Figure 2.1).
The densities n(t, a), p(t, a) and m(t, a) satisfy, for t > 0, the system
∂n
∂t
+ ∂n
∂a
= −(δ + β(E1(t)))n(t, a), a > 0,
∂p
∂t
+ ∂p
∂a
= −γ(E2(t))p(t, a), 0 < a < τ,
∂m
∂t
+ ∂m
∂a
= −µm(t, a), a > 0.
(2.2.1)
System (2.2.1) is completed by boundary conditions (for a = 0), that describe the flux
of cells entering each phase, and by initial conditions (for t = 0). Then the boundary
conditions of (2.2.1) are, for t > 0,
n(t, 0) = 2αp(t, τ),
p(t, 0) = β(E1(t))N(t),
m(t, 0) = KN (E3(t))N(t) + 2KP (E4(t))p(t, τ),
(2.2.2)
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Figure 2.1: Schematic representation of HSC dynamics. Solid arrows represent the
mechanisms taken into account: differentiation, cell division, reintroduction into the
proliferating phase, apoptosis and natural death. The dependency of the parameters
upon growth factors are represented by dashed lines. The dash-dotted line represents
the feedback control from mature cells to the growth factors.
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where
N(t) =
∫ +∞
0
n(t, a)da, P (t) =
∫ τ
0
p(t, a)da, M(t) =
∫ +∞
0
m(t, a)da,
and Ei(t), i = 1, 2, 3, 4, are growth factor concentrations. Initial conditions of (2.2.1)
are given by nonnegative L1-functions n0, p0 and m0, such that
n(0, a) = n0(a), m(0, a) = m0(a), for a ≥ 0,
p(0, a) = p0(a), for a ∈ [0, τ ].
(2.2.3)
In addition, we assume that
lim
a→+∞
n(t, a) = lim
a→+∞
m(t, a) = 0, for t ≥ 0.
The growth factor concentrations Ei(t), follow the evolution equations
E′i(t) = −kiEi(t) + fi(M(t)), (2.2.4)
where the coefficients ki > 0 are the degradation rates of the growth factors Ei. We as-
sume that the functionsM 7→ fi(M) are positive, decreasing and satisfy limM→+∞ fi(M) =
0.
2.3 Reduction to a delay differential system
The age-structured model (2.2.1)-(2.2.2)-(2.2.3)-(2.2.4) can be reduced to a delay dif-
ferential system. The method of characteristics implies, for t > 0 and a ∈ (0, τ),
that
p(t, a) =
p0(a− t) exp
(
−
∫ t
0 γ(E2(s))ds
)
, if 0 < t < a,
β(E1(t− a))N(t− a) exp
(
−
∫ t
t−a γ(E2(s))ds
)
, if 0 < a < t.
(2.3.1)
Integrating the first equation of (2.2.1) with respect to the age variable, we obtain
N ′(t) = −δN(t)− β(E1(t))N(t) + n(t, 0).
Using the first equation of (2.2.2), we obtain
N ′(t) = −(δ + β(E1(t)))N(t) + 2αp(t, τ).
Thanks to (2.3.1), we obtain
N ′(t) = −(δ + β(E1(t)))N(t)
+ 2α
{
p0(a− t) exp(−
∫ t
0 γ(E2(s))ds), if t < τ,
β(E1(t− τ))N(t− τ) exp(−
∫ t
t−τ γ(E2(s)) ds), if t > τ.
(2.3.2)
Integrating the last equation of (2.2.1) with respect to the age variable, we obtain
M ′(t) = −µM(t) +m(t, 0). (2.3.3)
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Then, using the last boundary condition of (2.2.2), we obtain
M ′(t) = −µM(t) +KN (E3(t))N(t) + 2KP (E4(t))p(t, τ).
We conclude that
M ′(t) = −µM(t) +KN (E3(t))N(t) + 2KP (E4(t))
×
{
p0(a− t) exp(−
∫ t
0 γ(E2(s))ds), if t < τ,
β(E1(t− τ))N(t− τ) exp(−
∫ t
t−τ γ(E2(s)) ds), if t > τ.
(2.3.4)
Note that, for t > τ , we have
P (t) =
∫ τ
0
β(E1(t− a))N(t− a) exp
(
−
∫ t
t−a
γ(E2(s))ds
)
da.
Then, the asymptotic behavior of P is related to E1, E2 and N . On the other hand,
N , M , and Ei, do not depend on P , then, we can focus on the study of the solutions
(N,M,Ei). One can notice that, on the interval [0, τ ] the functions (N,M,Ei) satisfy
a non-autonomous ordinary differential system, and for t > τ , they satisfy the delay
differential system
N ′(t) = −(δ + β(E1(t)))N(t)
+ 2αβ(E1(t− τ))N(t− τ) exp
(
−
∫ t
t−τ
γ(E2(s)) ds
)
,
M ′(t) = −µM(t) +KN (E3(t))N(t)
+ 2KP (E4(t))β(E1(t− τ))N(t− τ) exp
(
−
∫ t
t−τ
γ(E2(s)) ds
)
,
E′i(t) = −kiEi(t) + fi(M(t)),
(2.3.5)
with initial conditions solutions of the ordinary differential system (2.2.4)-(2.3.2)-
(2.3.4) defined on the interval [0, τ ]. For each continuous initial condition, the system
(2.3.5) has a unique solution, defined for t > τ (see Hale and Verduyn Lunel [58]).
From now on, we make a translation of the initial conditions so as to define them on
the interval [−τ, 0], as it can be found in Hale and Verduyn Lunel [58].
2.4 Positivity and boundedness of solutions
We focus on the positivity and boundedness properties of the solutions (N,M,Ei)
of system (2.3.5). The following result states that all solutions of system (2.3.5) are
nonnegative, provided that initial conditions are nonnegative.
Proposition 2.4.1. The solutions of system (2.3.5) associated with nonnegative initial
conditions are nonnegative.
Proof. Let (N(t),M(t), Ei(t)) be a solution of (2.3.5). Firstly, we check that N is
nonnegative. Assume that there exist t0 > 0 and ε ∈ (0, τ) such that N(t) > 0, for
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0 < t < t0, N(t0) = 0 and N(t) < 0, for t ∈ (t0, t0 + ε). Let t ∈ (t0, t0 + ε). It follows
from (2.3.5), that
N ′(t0) = 2αβ(E1(t0 − τ))N(t0 − τ) exp
(
−
∫ t0
t0−τ
γ(E2(s)) ds
)
> 0.
This gives a contradiction. Consequently, N(t) is nonnegative for t ≥ 0. Using a
similar reasoning, we prove that M(t) is nonnegative. Finally, the positivity of Ei(t)
follows from the fact that fi is positive.
We now concentrate on the boundedness properties of the solutions of system
(2.3.5). We start by proving the following lemma.
Lemma 2.4.2. The solution Ei(t) of (2.3.5) is strictly decreasing as long as Ei(t) >
fi(0)/ki, and either:
(i) Ei(t) > fi(0)/ki for all t ≥ 0 and then, limt→+∞Ei(t) = fi(0)/ki, or
(ii) there exists ti ≥ 0 such that Ei(ti) = fi(0)/ki and then, Ei(t) ≤ fi(0)/ki, for all
t ≥ ti.
Proof. Using the variation of constant formula, we can write
Ei(t) = e−kitEi(0) + e−kit
∫ t
0
ekisfi(M(s))ds, t ≥ 0.
Then, we deduce that
0 ≤ Ei(t) ≤ e−kitEi(0) +
fi(0)
ki
(1− e−kit) ≤ max
{
Ei(0),
fi(0)
ki
}
.
Therefore, Ei is bounded. Suppose that Ei(t) > fi(0)/ki. Then
E′i(t) = −kiEi(t) + fi(M(t)) < fi(0) + fi(M(t)) ≤ 0.
Consequently, Ei(t) is decreasing as long as Ei(t) > fi(0)/ki.
(i) Suppose that Ei(t) > fi(0)/ki, for all t ≥ 0. Then, Ei(t) is decreasing on
[0,+∞), and Li := limt→+∞Ei(t) exists. Assume by contradiction that Li > fi(0)/ki.
Then
E′i(t) + kiEi(t) = fi(M(t)) ≤ fi(0), t ≥ 0.
By taking the limit in this last equation, we obtain kiLi ≤ fi(0). This gives a contra-
diction. We conclude that limt→+∞Ei(t) = fi(0)/ki.
(ii) Suppose there exists ti ≥ 0 such that Ei(ti) = fi(0)/ki. Then
E′i(ti) = −fi(0) + fi(M(ti)) ≤ 0.
Our objective is to prove that Ei(t) ≤ fi(0)/ki, for all t ≥ ti. If we suppose the
existence of ε > 0 such that Ei(ti + ε) > fi(0)/ki, we obtain a contradiction, because
the function Ei(t) is strictly decreasing as long as Ei(t) > fi(0)/ki.
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Next, we state and prove a result regarding the boundedness property of the so-
lutions of (2.3.5). In the rest of the paper, we suppose that δ > 0. The case δ = 0
should be treated separately, and so it will not be considered here.
Proposition 2.4.3. Assume that(
2α exp
(
−τγ
(f2(0)
k2
))
− 1
)
β
(f1(0)
k1
)
< δ. (2.4.1)
Then the solutions of system (2.3.5) are bounded.
Proof. A direct application of Lemma 2.4.2 implies that Ei are always bounded. Fur-
thermore, it is not difficult to see that the boundedness of N implies the boundedness
of M . Then, we concentrate on the boundedness of N .
By (2.4.1) and the continuity of γ and β, we can take ε > 0 small enough such that(
2α exp
(
−τγ
(f2(0)
k2
+ ε
))
− 1
)
β
(f1(0)
k1
+ ε
)
< δ. (2.4.2)
Lemma 2.4.2 implies that there exits tε ≥ 0 such that Ei(t) ≤ fi(0)/ki + ε, for all
t ≥ tε. Consider the function
Zε(t) = N(t) + 2α exp
(
−τγ
(f2(0)
k2
+ ε
))(∫ t
t−τ
β(E1(θ))N(θ) dθ
)
, t ≥ tε + τ.
It follows that
Z ′ε(t) = N ′(t) + 2α exp
(
−τγ
(f2(0)
k2
+ ε
))(
β(E1(t))N(t)
− β(E1(t− τ))N(t− τ)
)
,
= −(δ + β(E1(t)))N(t)
+ 2αβ(E1(t− τ))N(t− τ) exp
(
−
∫ t
t−τ
γ(E2(s))ds
)
+ 2α exp
(
−τγ
(f2(0)
k2
+ ε
))
β(E1(t))N(t)
− 2α exp
(
−τγ
(f2(0)
k2
+ ε
))
β(E1(t− τ))N(t− τ).
This implies
Z ′ε(t)
= −
[
δ −
(
2α exp
(
−τγ
(f2(0)
k2
+ ε
))
− 1
)
β(E1(t))
]
N(t)
− 2α
(
exp(−τγ
(f2(0)
k2
+ ε
)
)− exp(−
∫ t
t−τ
γ(E2(s)) ds)
)
β(E1(t− τ))N(t− τ).
As the function γ is decreasing, we have
exp
(
−
∫ t
t−τ
γ(E2(s))ds
)
≤ exp
(
−τγ
(f2(0)
k2
+ ε
))
, t ≥ tε + τ.
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Then
Z ′ε(t) ≤ −
(
δ −
(
2α exp
(
−τγ
(f2(0)
k2
+ ε
))
− 1
)
β(E1(t))
)
N(t).
We have to consider two cases. Suppose that
2α exp
(
−τγ
(f2(0)
k2
+ ε
))
≤ 1.
Then Z ′ε(t) ≤ 0.
Now, suppose that
2α exp
(
−τγ
(f2(0)
k2
+ ε
))
> 1.
Since β is increasing, we have
β(E1(t)) < β
(f1(0)
k1
+ ε
)
.
Thanks to (2.4.2), we obtain
δ >
(
2α exp
(
−τγ
(f2(0)
k2
+ ε
))
− 1
)
β(E1(t)).
This implies Z ′ε(t) ≤ 0 for t ≥ tε + τ . We conclude that Zε is bounded. Consequently,
N is also bounded.
2.5 Existence of steady states
In this section, we study the existence of steady states of (2.3.5). Let (N,M,Ei) be a
steady state of (2.3.5). Then, it satisfies
(δ + β(E1))N = 2αβ(E1)Ne−τγ(E2),
µM = KN (E3)N + 2KP (E4)β(E1)Ne−τγ(E2),
kiEi = fi(M).
(2.5.1)
One can easily see that (0, 0, fi(0)/ki) is always a steady state (the trivial steady state).
A nontrivial steady state (N,M,Ei) 6= (0, 0, fi(0)/ki), satisfies
δ = (2αe−τγ(E2) − 1)β(E1),
N = µM
KN (E3) + 2KP (E4)β(E1)e−τγ(E2)
,
Ei =
fi(M)
ki
.
(2.5.2)
It is clear that, the existence and uniqueness of nontrivial steady state is equivalent to
finding M > 0, a solution of the equation
δ =
(
2α exp
(
−τγ
(f2(M)
k2
))
− 1
)
β(f1(M)
k1
). (2.5.3)
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Proposition 2.5.1. Assume that
δ <
(
2α exp
(
−τγ
(f2(0)
k2
))
− 1
)
β
(f1(0)
k1
)
. (2.5.4)
Then there exists a unique nontrivial steady state (N,M,Ei) of (2.3.5). If (2.5.4)
does not hold, then (0, 0, fi(0)/ki) is the only steady state of (2.3.5).
Proof. We define the function
Ψ(x) = ξ(x)η(x), x ≥ 0,
where
ξ(x) = 2α exp
(
−τγ(f2(x)
k2
)
)
− 1, η(x) = β
(f1(x)
k1
)
, x ≥ 0.
Then equation (2.5.3) becomes Ψ(x) = δ and inequality (2.5.4) can be written as
δ < Ψ(0). Note that limx→+∞ fi(x) = 0 and β(0) = 0. Then limx→+∞Ψ(x) = 0. We
conclude that (2.5.3) has at least one solution if and only if δ < Ψ(0). To prove the
uniqueness, we note that β is increasing, fi and γ are decreasing. Then, the functions ξ
and η are decreasing and satisfy limx→+∞ ξ(x) = 2αe−τγ(0)−1 and limx→+∞ η(x) = 0.
Firstly, we suppose that 2αe−τγ(0) − 1 ≥ 0. Then, ξ(0) > 0. Consequently, Ψ is
positive, decreasing on [0,+∞) and satisfies limx→+∞Ψ(x) = 0. We conclude that
(2.5.3) has a unique positive solution M if and only if δ < Ψ(0). Secondly, we suppose
that 2αe−τγ(0) − 1 < 0 and ξ(0) > 0. Then, there exists a unique M̃ > 0 such that
Ψ(M̃) = 0, Ψ(x) > 0 for 0 ≤ x < M̃ and Ψ(x) < 0 for x > M̃ . Consequently, Ψ
is positive and decreasing on the interval [0, M̃ ] with Ψ(M̃) = 0. Then (2.5.3) has a
unique solution M ∈ (0, M̃) if and only if δ < Ψ(0). The existence and uniqueness of
Ei and N follow immediately from (2.5.2). This completes the proof.
Note that condition (2.5.4) is equivalent to
1 ≥ α > αmin :=
δ + β(f1(0)/k1)
2β(f1(0)/k1)
= 12 +
δ
2β(f1(0)/k1)
,
0 ≤ τ < τmax :=
1
γ(f2(0)/k2)
ln
( 2αβ(f1(0)/k1)
δ + β(f1(0)/k1)
)
.
(2.5.5)
In the next section, we analyze the asymptotic behavior of the solutions of system
(2.3.5) by studying the asymptotic stability of its steady states.
2.6 Global asymptotic stability of trivial steady state
We assume, throughout this section, that the function β is continuously differentiable
on [0,+∞). We begin by establishing the global asymptotic stability of the trivial
steady state (0, 0, fi(0)/ki). First let us recall a useful lemma (see Gopalsamy [51]),
that will allow us to establish the next result.
Lemma 2.6.1. Let f : (a,+∞)→ R, a ∈ R, be a differentiable function. If limt→+∞ f(t)
exists and f ′(t) is uniformly continuous on (a,+∞), then
lim
t→+∞
f ′(t) = 0.
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Lemma 2.6.2. Let (N(t),M(t), Ei(t)) be a bounded solution of (2.3.5). Then, the
following three statements are equivalent
lim
t→+∞
N(t) = 0, lim
t→+∞
M(t) = 0, lim
t→+∞
Ei(t) = fi(0)/ki, i = 1, 2, 3, 4.
Proof. We begin by proving that limt→+∞N(t) = 0 if and only if limt→+∞M(t) = 0.
We first assume that limt→+∞N(t) = 0. We have M ′(t) = −µM(t) + F (t), with
F (t) = KN (E3(t))N(t) + 2KP (E4(t))β(E1(t− τ))
×N(t− τ) exp
(
−
∫ t
t−τ
γ(E2(s)) ds
)
.
Then limt→+∞ F (t) = 0. Using the variation of constant formula, we can write
M(t) = e−µtM(0) + e−µt
∫ t
0
eµsF (s)ds, t ≥ 0.
Let ε > 0 be fixed. Since N(t) tends to zero when t tends to +∞, there exits tε > 0
such that
F (t) < µε2 , e
−µt
(
M(0) +
∫ tε
0
eµsF (s)ds
)
<
ε
2 , for t ≥ tε.
Then, for t ≥ tε, we have
M(t) ≤ e−µt
(
M(0) +
∫ tε
0
eµsF (s)ds
)
+ e−µt
( ∫ t
tε
eµsF (s)ds
)
,
with
e−µt
( ∫ t
tε
eµsF (s)ds
)
≤ ε2
(
1− eµ(tε−t)
)
≤ ε2 .
Consequently, M(t) < ε for t ≥ tε. We have proved that limt→+∞M(t) = 0.
Secondly, we assume that limt→+∞M(t) = 0. Then the solution (N,M,Ei) is
bounded, and the derivative (N ′,M ′, E′i) is also bounded. Furthermore, M ′(t) is
differentiable for t > τ , and since N , M , Ei, N ′, M ′, E′i are bounded for t > τ ,
M ′′ is bounded. Then M ′ is uniformly continuous. Consequently, Lemma 2.6.1
implies that limt→+∞M ′(t) = 0. From the equation satisfied by M , we deduce
that limt→+∞ F (t) = 0. In particular, limt→+∞KN (E3(t))N(t) = 0. Suppose that
limt→+∞KN (E3(t)) = 0. That means that limt→+∞E3(t) = 0. Then, from the equa-
tion satisfied by E3, we deduce that limt→+∞ f3(M(t)) = 0. This gives a contradiction
because limt→+∞M(t) = 0 and f3(0) > 0. Then, we conclude that limt→+∞N(t) = 0.
Thirdly, we assume that limt→+∞M(t) = 0 and we will prove that limt→+∞Ei(t) =
fi(0)/ki. Thanks to Lemma 2.4.2, it suffices to prove the result for the case Ei(t) <
fi(0)/ki for all t > t̄. Without loss of generality, we can choose t̄ = 0. We put
Fi(t) = fi(0)/ki − Ei(t) and Gi(t) = fi(0)− fi(M(t)). Then, Fi satisfies the following
differential equation
F ′i (t) = −kiFi(t) +Gi(t),
with Fi(t) > 0 and Gi(t) > 0 for all t ≥ 0 and limt→+∞Gi(t) = 0. Then, using the
same argument as in the first part of this proof, we obtain limt→+∞ Fi(t) = 0. This
means that limt→+∞Ei(t) = fi(0)/ki.
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Finally, we suppose that limt→+∞Ei(t) = fi(0)/ki. Then by Lemma 2.6.1, we
have limt→+∞E′i(t) = 0. We deduce that limt→+∞ fi(M(t)) = fi(0). As the function
fi is continuous and strictly decreasing from [0,+∞) into (0, fi(0)], we conclude that
limt→+∞M(t) = 0. This completes the proof.
Next, we prove a result dealing with the global asymptotic stability of the trivial
steady state (0, 0, fi(0)/ki).
Theorem 2.6.3. Assume that (2.4.1) holds. That is to say that (0, 0, fi(0)/ki) is
the only steady state. Then, all solutions (N(t),M(t), Ei(t)) of (2.3.5) converge to
(0, 0, fi(0)/ki), i = 1, 2, 3, 4.
Proof. As in the proof of Proposition 2.4.3, we take ε > 0 small enough such that(
2α exp
(
−τγ
(f2(0)
k2
+ ε
))
− 1
)
β
(f1(0)
k1
+ ε
)
< δ,
and tε ≥ 0 such that Ei(t) ≤ fi(0)/ki + ε, for all t ≥ tε. Consider the functional
Vε : (C([tε, tε + τ ],R+))6 → R+, Defined by
Φ = (ϕ,ψ, χ1, χ2, χ3, χ4),
Vε(Φ) = ϕ(tε + τ) + 2α exp
(
− τγ
(f2(0)
k2
+ ε
))
×
∫ 0
−τ
β(χ1(θ + tε + τ))ϕ(θ + tε + τ) dθ.
The composition with the solution X(t) := (N(t),M(t), Ei(t)) of equation (2.3.5)
leads, for t ≥ tε + τ , to the function
t 7→ Vε(Xt) = N(t) + 2α exp
(
− τγ
(f2(0)
k2
+ ε
)) ∫ t
t−τ
β(E1(s))N(s)ds.
Then, the derivative along the solution of system (2.3.5) gives
d
dt
Vε(Xt)
= N ′(t) + 2α exp
(
− τγ
(f2(0)
k2
+ ε
))[
β(E1(t))N(t)− β(E1(t− τ))N(t− τ)
]
,
= −(δ + β(E1(t)))N(t)
+ 2αβ(E1(t− τ))N(t− τ) exp
(
−
∫ t
t−τ
γ(E2(s)) ds
)
+ 2α exp(−τγ
(f2(0)
k2
+ ε
)
)[β(E1(t))N(t)− β(E1(t− τ))N(t− τ)],
= −
(
δ −
[
2α exp(−τγ
(f2(0)
k2
+ ε
)
)− 1
]
β(E1(t)))N(t)
− 2α
[
exp(−τγ
(f2(0)
k2
+ ε
)
)− exp(−
∫ 0
−τ
γ(E2(t+ s)) ds)
]
× β(E1(t− τ))N(t− τ).
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Let −τ ≤ s ≤ 0. Since t ≥ tε + τ , then Ei(t+ s) < fi(0)ki + ε. Consequently, −γ(E2(s+
t)) < −γ(f2(0)k2 + ε) and β(E1(t)) < β(
f1(0)
k1
+ ε). This implies
exp
(
− τγ
(f2(0)
k2
+ ε
))
> exp
(
−
∫ 0
−τ
γ(E2(s+ t)) ds
)
,
δ >
[
2α exp
(
− τγ
(f2(0)
k2
+ ε
))
− 1
]
β(E1(t)).
Thus,
V̇ε(Φ) ≤ 0, for all Φ ∈ (C([tε, tε + τ ],R+))6,
where V̇ε is the derivative of Vε along the solutions of (2.3.5). Now, let
S := {Φ ∈ (C([tε, tε + τ ],R+))6 : V̇ε(Φ) = 0}.
We deduce that
S = {Φ ∈ (C([tε, tε + τ ],R+))6 : ϕ(tε + τ) = ϕ(tε) = 0}.
We also consider the set Ω, defined as the largest set in S which is invariant with
respect to system (2.3.5). Let Xt be a solution of (2.3.5) associated with an initial
condition Φ ∈ Ω. Then, Xt ∈ Ω for all t ≥ tε + τ is equivalent to N(t) = 0 for all
t ≥ tε + τ . Consequently,
Ω = {0} × (C([tε, tε + τ ],R+))5.
From Hale and Verduyn Lunel [58, page 143], all bounded solutions Xt of (2.3.5)
converge to Ω as t tends to +∞. From Proposition 2.4.1, all solutions of (2.3.5) are
bounded provided that (2.4.1) holds. Then, all solutions Xt converge to Ω. We deduce
that for all Φ ∈ (C([tε, tε + τ ],R+))6,
lim
t→+∞
N(t) = 0.
Then, from Lemma 2.6.2, we conclude that
lim
t→+∞
M(t) = 0 and lim
t→+∞
Ei(t) = fi(0)/ki, i = 1, 2, 3, 4.
This completes the proof.
Next, we linearize system (2.3.5) about its steady states, and we determine the
characteristic equation. Let (N,M,Ei) be a steady state of (2.3.5). We set
X(t) = N(t)−N, Y (t) = M(t)−M, Zi(t) = Ei(t)− Ei.
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The linearized system of (2.3.5) around (N,M,Ei) is
X ′(t) = −(δ + β(E1))X(t)− β′(E1)NZ1(t)
+ 2αβ(E1)e−τγ(E2)X(t− τ) + 2αNβ′(E1)e−τγ(E2)Z1(t− τ)
− 2ταNβ(E1)γ′(E2)e−τγ(E2)
∫ 0
−τ
Z2(t+ s) ds,
Y ′(t) = −µY (t) +KN (E3)X(t) +K ′N (E3)NZ3(t)
+ 2KP (E4)β(E1)e−τγ(E2)X(t− τ) + 2K ′P (E4)β(E1)Ne−τγ(E2)Z4(t)
+ 2KP (E4)β′(E1)Ne−τγ(E2)Z1(t− τ)
− 2τKP (E4)β(E1)Nγ′(E2)e−τγ(E2)
∫ 0
−τ
Z2(t+ s) ds,
Z ′i(t) = −kiZi(t) + f ′i(M)Y (t).
(2.6.1)
The above system has the form
U ′(t) = AU(t) +BU(t− τ) + C(
∫ 0
−τ
U(t+ s) ds), (2.6.2)
with U(t) = (X(t), Y (t), Zi(t))T ∈ R6, where
A =

−(δ + β(E1)) 0 −β′(E1)N 0 0 0
KN (E3) −µ 0 0 K ′N (E3)N NH4
0 f ′1(M) −k1 0 0 0
0 f ′2(M) 0 −k2 0 0
0 f ′3(M) 0 0 −k3 0
0 f ′4(M) 0 0 0 −k4

,
B =

H0 0 N H1 0 0 0
H0 0 N H1 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0

, C =

0 0 0 N H2 0 0
0 0 0 N H2 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0

,
with
H0 := 2αβ(E1)e−τγ(E2) ≥ 0,
H1 :=
dH0
dE1
= 2αβ′(E1)e−τγ(E2) ≥ 0,
H2 :=
dH0
dE2
= −2ταβ(E1)γ′(E2)e−τγ(E2) ≥ 0,
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and
H0 := 2KP (E4)β(E1)e−τγ(E2) ≥ 0,
H1 :=
dH0
dE1
= 2KP (E4)β′(E1)e−τγ(E2) ≥ 0,
H2 :=
dH0
dE2
= −2τKP (E4)β(E1)γ′(E2)e−τγ(E2) ≥ 0,
H4 :=
dH0
dE4
= 2K ′P (E4)β(E1)e−τγ(E2) ≥ 0.
The relationship between the expressions H0 and H0 is given by
αH0 = KP (E4)H0.
The characteristic equation associated to the steady state (N,M,Ei) is
∆(λ) = det
(
λI −A−Be−λτ − C
∫ 0
−τ
eλθ ds
)
= 0. (2.6.3)
Then, we have the following result.
Theorem 2.6.4. The trivial steady state of (2.3.5) is unstable when (2.5.4) holds.
Proof. When (N,M,Ei) = (0, 0, fi(0)/ki) system (2.6.2) becomes
U ′(t) = AU(t) +BU(t− τ), (2.6.4)
with U(t) = (X(t), Y (t), Zi(t))T ∈ R6,
A =

−(δ + β(f1(0)/k1)) 0 0 0 0 0
KN (f3(0)/k3) −µ 0 0 0 0
0 f ′1(0) −k1 0 0 0
0 f ′2(0) 0 −k2 0 0
0 f ′3(0) 0 0 −k3 0
0 f ′4(0) 0 0 0 −k4

,
and
B = 2β(f1(0)
k1
) exp
(
−τγ
(f2(0)
k2
))

α 0 0 0 0 0
KP (f4(0)/k4) 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0

.
The characteristic equation (2.6.3) becomes
∆(λ) = det(λI −A−Be−λτ ) = 0.
Then
∆(λ) = (λ+ µ)
4∏
i=1
(λ+ ki)∆(λ),
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where
∆(λ) = λ+ δ + β(f1(0)
k1
)− 2αβ(f1(0)
k1
) exp
(
− τ(λ+ γ(f2(0)
k2
))
)
.
The eigenvalues of (2.6.4) are λ = −µ < 0, λ = −ki < 0, i ∈ 1, 2, 3, 4 and roots of the
equation ∆(λ) = 0.
Let λ ∈ R. We have
∆′(λ) = 1 + 2ατβ(f1(0)
k1
) exp
(
− τ(λ+ γ(f2(0)
k2
))
)
> 0,
∆(0) = δ − 2α
(
exp
(
− τγ(f2(0)
k2
)
)
− 1
)
β
(f1(0)
k1
)
,
lim
λ→+∞
∆(λ) = +∞.
Thanks to (2.5.4), we have ∆(0) < 0. Thus, there exists λ0 > 0 such that ∆(λ0) = 0.
Hence, the instability of the trivial steady state holds.
The last theorem completes the global asymptotic stability of the trivial steady
state (0, 0, fi(0)/ki) obtained in Theorem 2.6.3, and allows us to entirely determine its
dynamics.
2.7 Local asymptotic stability of the positive steady state
We assume throughout this section, that condition (2.5.4) is satisfied, or equivalently
(2.5.5), to ensure the existence and uniqueness of the positive steady state (N,M,Ei)
of (2.3.5). The nature of the characteristic equation associated to the linearized system
around (N,M,Ei) induces some technical difficulties. To avoid these difficulties, we
make the following assumption
ki = k, fi = f, Ei = E, i = 1, 2, 3, 4.
Then system (2.3.5) becomes
N ′(t) = −(δ + β(E(t)))N(t)
+ 2αβ(E(t− τ))N(t− τ) exp
(
−
∫ t
t−τ
γ(E(s)) ds
)
,
M ′(t) = −µM(t) +KN (E(t))N(t)
+ 2KP (E(t))β(E(t− τ))N(t− τ) exp
(
−
∫ t
t−τ
γ(E(s)) ds
)
,
E′(t) = −kE(t) + f(M(t)).
(2.7.1)
The linearized system of (2.7.1) around the positive steady state (N,M,E) has the
form
U ′(t) = AU(t) +BU(t− τ) + C
(∫ 0
−τ
U(t+ s) ds
)
, (2.7.2)
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with U(t) = (X(t), Y (t), Z(t))T ∈ R3,
A =
−(δ + β(E)) 0 −β
′(E)N
KN (E) −µ K ′N (E)N + 2K ′P (E)β(E)Ne−τγ(E)
0 f ′(M) −k
 ,
B =
 2αβ(E)e−τγ(E) 0 2αNβ′(E)e−τγ(E)2KP (E)β(E)e−τγ(E) 0 2KP (E)β′(E)Ne−τγ(E)
0 0 0
 ,
C =
0 0 −2ταNβ(E)γ′(E)e−τγ(E)0 0 −2τKP (E)β(E)Nγ′(E)e−τγ(E)
0 0 0
 .
The associated characteristic equation becomes
∆(λ) = det
(
λI −A−Be−λτ − C
∫ 0
−τ
eλθ ds
)
= 0. (2.7.3)
The condition (2.5.5) becomes
1 ≥ α > αmin :=
1
2 +
δ
2β(f(0)/k) ,
0 ≤ τ < τmax :=
1
γ(f(0)/k) ln
( 2αβ(f(0)/k)
δ + β(f(0)/k)
)
.
(2.7.4)
First, let us suppose that τ = 0. Then (2.7.2) becomes
U ′(t) = (A+B)U(t), (2.7.5)
where
A+B =
−(δ − (2α− 1)β(E)) 0 (2α− 1)β′(E)NΛ(E) −µ Λ′(E)N
0 f ′(M) −k
 ,
with Λ(E) = KN (E) + 2KP (E)β(E). In fact, under condition (2.7.4), the steady state
(N,M,E) satisfies
(2α− 1)β(E) = δ, Λ(E)N = µM, kE = f(M).
Then the characteristic equation of (2.7.5),
det(λI −A−B) = 0,
becomes
λ
[
(λ+ µ)(λ+ k)− f ′(M)Λ′(E)N
]
− (2α− 1)Λ(E)f ′(M)β′(E)N = 0.
This is equivalent to
λ3 + a1λ2 + a2λ+ a3 = 0, (2.7.6)
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where
a1 = µ+ k > 0, a2 = µk − f ′(M)Λ′(E)N > 0,
a3 = −(2α− 1)Λ(E)f ′(M)β′(E)N > 0.
We have
a1a2 − a3 = µk(µ+ k)−Nf ′(M)[(µ+ k)Λ′(E)− (2α− 1)Λ(E)β′(E)].
Then, by applying the Ruth-Hurwitz criterion, we obtain the following lemma.
Lemma 2.7.1. All roots of (2.7.6) have negative real parts if and only if
µk(µ+ k)−Nf ′(M)
[
(µ+ k)Λ′(E)− (2α− 1)Λ(E)β′(E)
]
> 0. (2.7.7)
We also have the following lemma.
Lemma 2.7.2. Assume that
µ+ k > (2α− 1)Λ(β
−1(δ/2α− 1))β′(β−1(δ/2α− 1))
Λ′(β−1(δ/2α− 1)) , (2.7.8)
Then, all roots of (2.7.6) have negative real parts.
Proof. Since f ′(M) < 0, Λ′(E) > 0 and β′(E) > 0, the hypothesis
(µ+ k)Λ′(E) > (2α− 1)Λ(E)β′(E)
implies that (2.7.7) is satisfied. Furthermore, we have E = β−1(δ/2α− 1). Then,
(2.7.8) implies (2.7.7). Consequently, if (2.7.8) is satisfied, then all roots of (2.7.6)
have negative real parts.
Theorem 2.7.3. Assume that (2.5.4) and (2.7.7) hold. Then there exists τ∗ ∈ [0, τmax)
such that the positive steady state (N,M,E) is locally asymptotically stable for τ ∈
[0, τ∗).
Proof. A direct application of Lemma 2.7.1 implies that (N,M,E) is locally asymp-
totically stable when τ = 0. Furthermore, ∆ := ∆(λ, τ) given by (2.7.3) is analytic in
λ and τ . Then, as τ varies the zeros of λ 7→ ∆(λ, τ) stay in the open left half-plane
for τ small enough. If instability occurs for a particular value of τ , a characteristic
root must intersect the imaginary axis. Then, there exists τ∗ ∈ [0, τmax) such that for
τ ∈ [0, τ∗), all the roots of (2.7.3) have negative real parts.
2.8 Numerical illustrations
In this section, we perform some numerical simulations to illustrate the behavior of the
steady states. Let us choose the functions β, γ , KP , KN and the negative feedback f
as follows
β(E) = β̂E1 + E , γ(E) =
γ0
1 + Ea , KP (E) =
K̂PE
1 + E ,
KN (E) =
K̂NE
1 + E , f(M) =
f0
1 +M b ,
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with
δ + β̂ + K̂N ≤ 1 and α+ K̂P ≤ 1.
From (2.5.5) the positive steady state (N,M,E) exists if and only if
1 ≥ α > αmin :=
1
2 +
δ
2β(f1(0)/k1)
,
0 ≤ τ < τmax :=
1
γ(f2(0)/k2)
ln
( 2αβ(f1(0)/k1)
δ + β(f1(0)/k1)
)
.
We fix all the parameters except the delay τ . The values of the fixed parameters
are δ = 0.08 day−1, µ = 0.05 day−1, k = 0.6 day−1, α = 0.8, β̂ = 0.8 day−1, γ0 =
0.2 day−1, a = 3, K̂P = 0.18 day−1, K̂N = 0.1 day−1, f0 = 1, b = 7. With these
values, we have τmax = 9.052 days and αmin = 0.58. Then, the above condition of
existence of positive steady state becomes 0 ≤ τ < 9.052.
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Figure 2.2: Global asymptotic stability of the trivial steady state (N = 0,M = 0).
When τ = 9.5 days > τmax = 9.052 days, the trivial steady state is the only steady
state and it is globally asymptotically stable.
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Figure 2.3: Local asymptotic stability of the positive steady state (N,M). When
τ = 1 day < τmax = 9.052 days, the positive steady state is locally asymptotically
stable
Chapter 3
Hematopoietic Stem Cells dynamics
model with state dependent delay∗
Abstract
We propose and analyze a mathematical model describing the dynamics of a hematopoi-
etic stem cell population, in which the duration of the cell cycle depends upon the total
population of quiescent cells. The method of characteristics reduces the age-structured
model to a system of differential equations with a state-dependent delay. We perform
a detailed stability analysis of the resulting delay differential system. By construct-
ing a Lyapunov-Razumikhin function, we obtain a sufficient condition for the global
asymptotic stability of the trivial steady state, describing cell’s dying out. It is shown
that a unique non-trivial steady state can appear through a transcritical bifurcation of
the trivial steady state. The analysis of the positive steady state’s behavior concludes
to the existence of a Hopf bifurcation and gives criteria for stability switches. We
confirmed the analytical results by numerical simulations.
3.1 Age-structured partial differential model
We consider two cell population densities in resting and proliferating phase, denoted
respectively by n(t, a) and p(t, a), which have spent a time a ≥ 0 in their phase at time
t ≥ 0.
Resting cells are assumed to die at a constant rate δ > 0, which can also take into
account cell differentiation. They can be introduced into the proliferating phase with
a rate β in order to divide, which is supposed to depend upon the total population of
quiescent cells (see Mackey [76])
N(t) =
∫ ∞
0
n(t, a)da. (3.1.1)
The function β is assumed to be continuously differentiable, bounded and posi-
tive. Furthermore, we assume that β is decreasing with limx→+∞ β(x) = 0. These
∗M. Adimy, Y. Bourfia, M. L. Hbid, Hematopoietic Stem Cells dynamics model with state depen-
dant delay, soon to be submitted.
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assumptions describe the fact that the proliferation rate is a decreasing function of the
quiescent population.
It is usually believed that the function β is a monotone decreasing Hill function
(see [76]), given by
β(x) = β0θ
r
θr + xr , x ≥ 0, (3.1.2)
with β0 > 0, θ ≥ 0 and r > 0. The parameter β0 is the maximal rate of reentry
into proliferation, θ is the number of resting cells for which β possesses a maximal
exchange rate with the resting phase, and r describes the sensitivity of the population
with regards to the changes it may undergo.
The population of proliferating cells can die by apoptosis at a constant rate γ ≥ 0.
During mitosis, cells at age τ divide into two daughter cells that immediately enter the
resting phase, thus completing the cell cycle. We assume that the cell cycle duration τ
depends upon the total population of quiescent cells given by (3.1.1), i.e., τ = τ(N(t))
The function τ is supposed to be bounded, positive, continuously differentiable
(C2) and increasing (a deficiency of hematopoietic stem cells is supposed to shorten
the cell cycle duration). We define
τ0 := inf
x≥0
τ(x) = τ(0) and τmax = sup
x≥0
τ(x).
The densities n(t, a) and p(t, a) satisfy, for t > 0, the system
∂n
∂t
+ ∂n
∂a
= − (δ + β(N(t)))n, a > 0, t > 0, (3.1.3)
∂p
∂t
+ ∂p
∂a
= −γp, 0 < a < τ(N(t)), t > 0, (3.1.4)
where N(t) denotes the total population of resting cells, defined by (3.1.1), with initial
conditions given by nonnegative L1 functions n0 and p0 such that
n(0, a) = n0(a), a ≥ 0 and p(0, a) = p0(a), a ∈ [0, τ(N(0))]. (3.1.5)
The boundary conditions of (3.1.3)-(3.1.4), describing the flux of cells between the
two phases, are given by
n(t, 0) = 2
(
1− τ ′(N(t))N ′(t)
)
p(t, τ (N (t))), (3.1.6)
p(t, 0) = β(N(t))N(t). (3.1.7)
Moreover,in order to give meaning to the total population N(t), we suppose that
lima→+∞ n(t, a) = 0.
Denote by P (t) the total population of proliferating stem cells at time t. Then
P (t) =
∫ τ(N(t))
0
p(t, a)da, t ≥ 0.
Integrating (3.1.3) with respect to the age variable, and using (3.1.6), we obtain
N ′(t) = −δN(t)− β(N(t))N(t) + 2
(
1− τ ′(N(t))N ′(t)
)
p(t, τ (N (t))), for t ≥ 0.
(3.1.8)
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Using the method of characteristics (see Webb [118]), the solution p(t, a) of (3.1.4),
(3.1.7) and (3.1.5) is given, for t > 0 and 0 < a < τ(N(t)), by
p(t, a) =
{
p0(a− t)e−γt, if 0 ≤ t < a,
β(N(t− a))N(t− a)e−γa, if 0 ≤ a ≤ t.
(3.1.9)
Since resting cells are introduced into the proliferating phase with a rate β, then p0(0),
the population of cells introduced at time t = 0 into the cell cycle, should satisfy the
classical compatibility condition
p0(0) = β(N(0))N(0). (3.1.10)
This condition ensures the continuity of p(t, a) on the line t = a.
Note that
P (t)=

e−γt
(∫ t
0
eγθβ(N(θ))N(θ)dθ +
∫ τ(N(t))−t
0
p0(θ)dθ
)
, t < τ(N(t)),
e−γt
∫ t
t−τ(N(t))
eγθβ(N(θ))N(θ)dθ, t ≥ τ(N(t)).
(3.1.11)
The variable P (t) is straightforwardly continuous for t ≥ 0, and since τ is continuously
differentiable it is also continuously differentiable provided that (3.1.10) holds true.
Using (3.1.9), we finally obtain, for 0 ≤ t ≤ τ(N(t)),
N ′(t) = − (δ + β(N(t)))N(t) + 2
(
1− τ ′(N(t))N ′(t)
)
p0(τ(N(t))− t)e−γt, (3.1.12)
and, for t > τ(N(t)),
N ′(t)=− (δ+β(N(t)))N(t)+2
(
1−τ ′(N(t))N ′(t)
)
e−γτ(N(t))β(N(t−τ(N(t))))N(t−τ(N(t))).
(3.1.13)
Equation (3.1.13) becomes , for t > τ(N(t)),
N ′(t) = −δN (t)− β (N (t))N (t) + 2β (N (t− τ(N(t))))N (t− τ(N(t))) e
−γτ(N(t))
1 + 2τ ′(N(t))e−γτ(N(t))β (N (t− τ(N(t))))N (t− τ(N(t)))
(3.1.14)
Moreover,
N(0) =
∫ ∞
0
n0(a)da.
One can notice that problem (3.1.12)–(3.1.14) is a nonlinear nonautonomous or-
dinary differential equation for t < τ(N(t)), whereas, for t ≥ τ(N(t)), it is a system
of differential equations with state-dependent delay. Let us concentrate on system
(3.1.12)–(3.1.14) for t ∈ [0, τmax].
Consider the differential equation
dx
dt
(t)=

−δx(t)− β(x(t))x(t) + 2
(
1− τ ′(x(t))x′(t)
)
p0(τ(x(t))− t)e−γt, 0 ≤ t ≤ τ(x(t)),
−δx (t)− β (x (t))x (t) + 2β (x (t− τ(x(t))))x (t− τ(x(t))) e−γτ(x(t))
1 + 2τ ′(x(t))e−γτ(x(t))β (x (t− τ(x(t))))x (t− τ(x(t)))
, τ(x(t)) < t ≤ τmax,
x(0)=
∫ ∞
0
n0(a)da.
(3.1.15)
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For a smooth enough function p0 satisfying (3.1.10), (3.1.15) has a unique continuously
differentiable solution φ defined on [0, τmax] (see Walther [116]). Then the equation
(3.1.14) becomes the following delay differential equation, for t ≥ τmax,
dy
dt
(t) = −δy (t)− β (y (t)) y (t) + 2β (y (t− τ(y(t)))) y (t− τ(y(t))) e
−γτ(y(t))
1 + 2τ ′(y(t))e−γτ(y(t))β (y (t− τ(y(t)))) y (t− τ(y(t)))
,
y(θ) = φ(θ), 0 ≤ θ ≤ τmax.
Thus, by making a change of variable N(t) := y(t + τmax), system (3.1.12)–(3.1.14)
can be written as a state-dependent delay differential equation for t ≥ 0,
N ′(t) = −δN (t)− β (N (t))N (t) + 2β (N (t− τ(N(t))))N (t− τ(N(t))) e
−γτ(N(t))
1 + 2τ ′(N(t))e−γτ(N(t))β (N (t− τ(N(t))))N (t− τ(N(t)))
,
(3.1.16)
with, for θ ∈ [−τmax, 0], N(θ) = φ(θ + τmax).
Existence and uniqueness of solutions of (3.1.16) cannot be easily deduced. Equa-
tion (3.1.16) writes
x′(t) = g(x(t), x(t− τ(x(t)))) for t ≥ 0,
where the function g : (R+)2 → R is given by
g(x, y) = −δx− β(x)x+ 2β(y)ye
−γτ(x)
1 + 2τ ′(x)e−γτ(x)β (y) y
, (x, y) ∈ (R+)2.
This equation can also be written in the following general form
x′(t) = f(xt), for t ≥ 0, (3.1.17)
where xt is defined by xt(θ) = x(t+ θ) for θ ∈ [−τmax, 0], and the function f : C → R
is given, for φ ∈ C, the space of continuous functions on [−τmax, 0], by
f(φ) = g(φ(0), φ(−τ(φ(0)))).
Since the functions β(x) and τ(x) are continuously differentiable on [0,+∞), then g
is also continuously differentiable on (R+)2. Therefore existence and uniqueness of a
solution of (3.1.16) defined on [0,+∞) for an initial condition belonging to C1, the
space of continuously differentiable function on [−τmax, 0], follow from Mallet-Paret et
al. [84]. One may note that it is not reasonable to expect a well-posed state-dependent
delay differential problem by searching for solutions in C (see Walther [116]).
One can notice that equation (3.1.16) does not depend on the proliferating cell
population P , whereas the converse is not true.
3.2 Properties of the model and existence of steady states
We focus, in this section, on the positivity and boundedness properties of solutions of
(3.1.16).
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We suppose, from now on, that existence and uniqueness of solutions of (3.1.16)
hold for t ∈ [−τmax,+∞).
Since we’re dealing with cell population counts, it is imperative to prove positivity
and boundedness of solutions of (3.1.16). Those properties are stated in the following
proposition.
Proposition 3.2.1. The solutions of (3.1.16) are nonnegative, and provided that δ > 0
they are bounded.
Proof. These results are straightforward and can be obtained, for instance, using a
method similar to the one presented in Adimy et al. [9].
The expression of P (t) in (3.1.11) gives more detailed information about the influ-
ence of the behavior of N(t) on the stability and periodicity of the solutions P (t). The
following lemma, which states these results, is immediately obtained by using (3.1.11).
Lemma 3.2.2. Let (P (t), N(t)) be a solution of (3.1.11) and (3.1.16). If N∞ :=
limt→∞N(t) exists, then
lim
t→∞
P (t) =

N∞β (N∞)
(
1− e−γτ(N∞)
γ
)
, if γ > 0,
N∞β (N∞) τ(N∞), if γ = 0.
If N(t) is T−periodic, then P (t) is also T−periodic.
In particular, Lemma 3.2.2 establishes the influence of (3.1.16) on the stability of
the entire system. We now focus on the existence of steady states of (3.1.16).
Proposition 3.2.3. Assume δ > 0 and
τ0 <
1
γ
ln
( 2β(0)
β(0) + δ
)
. (3.2.1)
Then equation (3.1.16) has two steady states N ≡ 0 and N ≡ N∗ > 0, where
(2e−γτ(N∗) − 1)β(N∗) = δ. (3.2.2)
If (3.2.1) does not hold, then N ≡ 0 is the only steady state of (3.1.16).
Proof. Define, for N ≥ 0, the function χ(N) := (2e−γτ(N) − 1)β(N). Then
χ(0) = (2e−γτ0 − 1)β(0) > δ and lim
N→+∞
χ(N) = 0.
Consequently, equation (3.2.2) has at least one positive solution N∗. Moreover, since
τ is increasing then χ is decreasing, and provided that χ(N) > 0, N∗ is unique.
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3.3 Linearization and Characteristic Equation
We are interested in the asymptotic stability of the two steady states of system (3.1.16),
N ≡ 0 and N ≡ N∗. To reach our objective, we linearize system (3.1.16) about one of
its steady states and determine the associated characteristic equation.
Let J : C1 → R be the map defined, for φ ∈ C1, by
J(φ) = φ (−τ (φ(0))) .
The derivatives of J have the form
d
dφ
J (φ)ψ = −τ ′ (φ(0))φ′ (−τ(φ(0)))ψ(0) + ψ (−τ(φ(0))) , φ, ψ ∈ C1.
Then, for a steady state x∗ ∈ {0, N∗} of (3.1.16), the linearized function f of (3.1.17)
around x∗ is, for ψ ∈ C1,
Df(x∗)ψ = − δ + β(x
∗) + β′(x∗)x∗(
1 + 2τ ′(x∗)e−γτ(x∗)β(x∗)x∗
)2ψ(0)
−2 1 + x
∗τ
′(x∗) (δ + β(x∗))(
1 + 2τ ′(x∗)e−γτ(x∗)β(x∗)x∗
)2 γe−γτ(x∗)τ ′(x∗)β(x∗)x∗ψ(0)
−2 δ + β(x
∗) + β′(x∗)x∗(
1 + 2τ ′(x∗)e−γτ(x∗)β(x∗)x∗
)2 e−γτ(x∗)τ ′(x∗)β(x∗)x∗ψ(0)
+2 δ + β(x
∗)− 2β(x∗)e−γτ(x∗)(
1 + 2τ ′(x∗)e−γτ(x∗)β(x∗)x∗
)2 e−γτ(x∗)τ ′′(x∗)β(x∗)(x∗)2ψ(0)
+2 1 + x
∗τ ′(x∗) (δ + β(x∗))(
1 + 2τ ′(x∗)e−γτ(x∗)β(x∗)x∗
)2 e−γτ(x∗)[β′(x∗)x∗ + β(x∗)]ψ(−τ(x∗)).
Using (3.2.2), it follows that the characteristic equation associated with the lineariza-
tion of (3.1.16) around x∗ is
∆(λ) = λ+ δ + β + α
[
1 + ζτ ′(x∗)
]
τ ′(x∗)e−γτ(x∗)
+ η
[
δ + β
]
τ ′(x∗)e−γτ(x∗)
− 2β
[
1 + ζτ ′(x∗)
]
e−γτ(x
∗)e−λτ(x
∗), (3.3.1)
where
α = 2γβ(x∗)x∗, β = β(x∗) + β′(x∗)x∗, η = 2β(x∗)x∗,
and
ζ = x∗ (δ + β(x∗)) .
In the next section we focus on the stability of the trivial steady state of (3.1.16).
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3.4 Global Asymptotic Stability of the Trivial Steady State
First, we are interested in the local asymptotic stability of the trivial steady state of
(3.1.16). The characteristic equation (3.3.1) becomes, when x∗ = 0,
∆(λ) = λ+ δ + β(0)− 2β(0)e−γτ0e−λτ0 .
Let λ ∈ R. We have
d∆
dλ
(λ) = 1 + 2τ0e−γτ0β(0)e−λτ0 > 0,
∆(0) = δ + β(0)− 2β(0)e−γτ0 = δ −
(
2e−γτ0 − 1
)
β(0),
and limλ→∞∆(λ) = +∞. Then there exists λ0 ∈ R, which is unique, such that ∆(λ0) =
0. When (3.2.1) holds, then ∆(0) < 0, so λ0 > 0, which proves the instability of the
trivial steady state.
When (3.2.1) does not hold, we show that all roots λ 6= λ0 of ∆ satisfy Re(λ) < λ0.
Suppose that λ = ρ+ iσ is a root of ∆ such that λ 6= λ0.
Considering the real parts of ∆ = 0 we get
ρ− λ0 = 2β(0)e−γτ0
(
e−ρτ0 cos(στ0)− e−λ0τ0
)
. (3.4.1)
By contradiction, we suppose that ρ > λ0 then e−ρτ0 cos(στ0)− e−λ0τ0 < 0. We obtain
a contradiction, thus ρ ≤ λ0. Now, if ρ = λ0, (3.4.1) implies
cos(στ0) = 1, for τ0 ≥ 0.
It follows that sin(στ0) = 0, considering the imaginary part of equation ∆ = 0 we get
σ + 2β(0)e−γτ0e−ρτ0 sin(στ0) = 0,
then σ = 0 and λ = λ0 which gives a contradiction. Therefore ρ < λ0.
We can now conclude that the trivial steady state N ≡ 0 of (3.1.16) is locally
asymptotically stable when
1
γ
ln
( 2β(0)
β(0) + δ
)
< τ0 ≤
1
γ
ln
(2β(0)
δ
)
,
and unstable when
τ0 <
1
γ
ln
( 2β(0)
β(0) + δ
)
.
When condition (3.2.1) holds and the trivial steady state N ≡ 0 is the only equi-
librium, we can give a necessary and sufficient condition for N ≡ 0 to be globally
asymptotically stable using a Lyapunov-Razumikhin function (see [57]).
The following result deals with the global asymptotic stability of the trivial steady
state.
Theorem 3.4.1. Assume
1
γ
ln
(2β(0)
δ
)
< τ0. (3.4.2)
Then the trivial steady state of (3.1.16) is globally asymptotically stable.
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Proof. Consider the Lyapunov function V : R+ → R+ given by V (x) = x2/2. We
have, for x ∈ R+, u(x) ≤ V (x) ≤ v(x), with u(x) = x2/2 and v(x) = x2.
Define p : R+ → R+ by p(x) = xe2ατ(
√
2x), x ∈ R+, with 0 < α < min{γ, γ −
ln(2β(0)/δ)/τ0}. Let N be a solution of (3.1.16) such that, for t ≥ 0, θ ∈ [−τmax, 0],
V (N(t+ θ)) < p (V (N(t))) . (3.4.3)
Then, for t ≥ 0, N(t− τ(N(t))) ≤ eατ(N(t))N(t). It follows that, for t ≥ 0,
V̇ (N(t)) = − (δ + β(N(t)))N(t)
2
1 + 2τ ′(N(t))e−γτ(N(t))β (N (t− τ(N(t))))N (t− τ(N(t)))
+ 2e
−γτ(N(t))β (N(t− τ(N(t))))N(t− τ(N(t)))N(t),
1 + 2τ ′(N(t))e−γτ(N(t))β (N (t− τ(N(t))))N (t− τ(N(t)))
≤ −δN(t)2 + 2e−γτ(N(t))β(0)eατ(N(t))N(t)2,
= −
[
δ − 2e−(γ−α)τ(N(t))β(0)
]
N(t)2.
(3.4.4)
LetW : R+ → R be the map defined, for x ∈ R+, byW (x) =
[
δ − 2e−(γ−α)τ(x)β(0)
]
x2.
From (3.4.2), W is a positive nondecreasing function.
Moreover, (3.4.4) gives V̇ (N(t)) ≤ −W (N(t)) whenever (3.4.3) holds true. Since
u(r)→∞ as r →∞, conditions of [56, Theorem 5.2] hold and so the conclusion.
In the next section, we focus on the behavior of the positive steady state of (3.1.16).
3.5 Transcritical Bifurcation and Hopf Bifurcation
This section is dedicated to the local asymptotic stability analysis of the positive steady
state N ≡ N∗ of equation (3.1.16).
Throughout this section, we consider the function τ to be given by τ(x) = µτ̃(x),
where µ is a positive parameter and τ̃ : R+ → R+ is a positive, increasing, bounded
and differentiable function. Equation (3.1.16) reads
N ′(t) = −δN (t)− β (N (t))N (t) + 2β (N (t− µτ̃(N(t))))N (t− µτ̃(N(t))) e
−γµτ̃(N(t))
1 + 2µτ̃ ′(N(t))e−γµτ̃(N(t))β (N (t− µτ̃(N(t))))N (t− µτ̃(N(t)))
,
(3.5.1)
Moreover, to ensure the existence of the positive steady state N∗ of (3.5.1), we assume
that condition (3.2.1) holds. Condition (3.2.1) is equivalent to
β(0) > δ and 0 ≤ µ < 1
τ̃(0)γ ln
( 2β(0)
δ + β(0)
)
:= µ. (3.5.2)
Inequalities (3.5.2) describe a situation in which the maximal introduction rate β(0)
has to be larger than the mortality rate δ and where the cell cycle duration τ cannot
take too long in order for system (3.5.1) to exhibit a positive steady state other than
the trivial one describing the cell’s dying out.
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The positive steady state N∗ depends upon the parameter µ and is given implicitly
by (
2e−γµτ̃(N∗(µ)) − 1
)
β (N∗(µ)) = δ, µ ∈ [0, µ). (3.5.3)
Using the Implicit Functions Theorem, we find that N∗ is a decreasing continuously
differentiable function of µ. Furthermore, from (3.5.2) and (3.5.3), one obtains
N∗(µ = 0) = β−1(δ) and lim
µ→µ
N∗(µ) = 0. (3.5.4)
From (3.3.1), the characteristic equation associated with N∗(µ) is written as
∆(λ, µ) = λ+ δ + β(µ) + α(µ)
[
1 + µζ(µ)τ̃ ′(N∗ (µ))
]
µτ ′(N∗ (µ))e−γµτ̃(N∗(µ))
+η(µ)
[
δ + β(µ)
]
µτ ′(N∗ (µ))e−γµτ̃(N∗(µ))
− 2β(µ)
[
1 + µζ(µ)τ ′(N∗ (µ))
]
e−γµτ̃(N
∗(µ))e−λµτ̃(N
∗(µ)), (3.5.5)
where
α(µ) = 2γβ(N∗ (µ))N∗ (µ) , β(µ) = β(N∗ (µ)) + β′(N∗ (µ))N∗ (µ) ,
η(µ) = 2β(N∗ (µ))N∗ (µ) and ζ(µ) = N∗ (µ) (δ + β(N∗ (µ))) .
Now, we investigate local asymptotic stability of N∗(µ) in a neighborhood of µ.
The following result states the existence of a transcritical bifurcation of the positive
steady state when µ = µ.
Theorem 3.5.1. When µ = µ, the positive steady state undergoes a transcritical
bifurcation, that is when µ increases and remains in the interval [0, µ) close to µ, the
positive steady state is locally asymptotically stable whereas the trivial steady state is
unstable, and when µ > µ the trivial steady state is locally asymptotically stable and is
the only steady state of (3.5.1).
Proof. First, notice that when β(µ) > 0 then characteristic roots of (3.5.5) have neg-
ative real parts. Indeed, assume β(µ) > 0 and consider ∆(λ, µ) as a function of real
λ. Then λ 7→ ∆(λ, µ) is an increasing function such that limλ→+∞∆(λ, µ) = +∞ and
using the definitions of α(µ), β(µ), η(µ), ζ(µ) and the fact that N∗(µ) is a steady state
of (3.5.1) we get
∆(0, µ) = − 2µδβ′(N∗ (µ))N∗ (µ) τ ′(N∗ (µ))e−γµτ̃(N∗(µ))
− (2e−γµτ̃(N∗(µ)) − 1)N∗(µ)β′(N∗(µ))
+ α(µ)
[
1 + µζ(µ)τ̃ ′(N∗ (µ))
]
µτ ′(N∗ (µ))e−γµτ̃(N∗(µ)),
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we easily see that
∆(0, µ) > 0.
Thus, there exists a unique λ∗ < 0 such that ∆(λ∗, µ) = 0. Separating real and
imaginary parts in (3.5.5), one can easily show that all characteristic roots λ 6= λ∗
satisfy Re(λ) < λ∗. The local asymptotic stability of the positive steady state when
β(µ) > 0 immediately follows.
Finally, one has to note that when µ is close to µ, µ < µ, then N∗(µ) is close to
zero (see (3.5.4)), therefore β(µ) ≈ β(0) > 0. The conclusion follows.
Local asymptotic stability of the positive steady state when µ = 0 is established in
the following lemma.
Lemma 3.5.2. Assume µ = 0. Then the steady state N∗ of system (3.5.1) is locally
asymptotically stable.
Proof. Let µ = 0. From (3.5.5), ∆(λ, 0) = λ + δ − β(0). Then, λ = β(0) − δ is
the unique eigenvalue associated with the characteristic equation. On the other hand,
N∗(0) = β−1(δ) > 0, so λ = β′(N∗(0))N∗(0) < 0. This concludes the proof.
Thus, N∗(µ) is locally asymptotically stable for µ = 0 and the stability can be lost
as µ increases away from 0, with µ < µ, only if purely imaginary characteristic roots
appear. One may note that N∗(µ) is locally asymptotically stable for µ < µ, µ close
to µ (see Theorem 3.5.1), so if stability is lost as µ increases away from zero a second
switch must be observed as µ keeps on increasing and reaches µ.
Define, for µ ∈ [0, µ),
b(µ) = δ+β(µ)+
(
η(µ)
[
δ + β(µ)
]
+ α(µ)
[
1 + µζ(µ)τ̃ ′(N∗ (µ))
])
µτ̃ ′(N∗ (µ))e−γµτ̃(N∗(µ))
and
c(µ) = − 2β(µ)
[
1 + µζ(µ)τ ′(N∗ (µ))
]
e−γµτ̃(N
∗(µ)).
Then (3.5.5) becomes
∆(λ, µ) = λ+ b(µ) + c(µ)e−λµτ̃(N∗(µ)). (3.5.6)
In the following, we investigate the existence of purely imaginary roots of (3.5.6).
It is obvious that λ = 0 is not a characteristic root of (3.5.6). Indeed,
b(µ) + c(µ) = − 2µδβ′(N∗ (µ))N∗ (µ) τ ′(N∗ (µ))e−γµτ̃(N∗(µ))
− (2e−γµτ̃(N∗(µ)) − 1)N∗(µ)β′(N∗(µ))
+ 2γβ(N∗ (µ))N∗ (µ)
[
1 + µζ(µ)τ̃ ′(N∗ (µ))
]
µτ ′(N∗ (µ))e−γµτ̃(N∗(µ)),
Since δ − (2e−γµτ̃(N∗(µ)) − 1)β(N∗(µ)) = 0, we obtain 2e−γµτ̃(N∗(µ)) − 1 > 0 and
∆(0, µ) = b(µ) + c(µ) > 0.
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It follows that λ = 0 is not an eigenvalue.
Let λ = iω, ω > 0 be a pure imaginary eigenvalue of (3.5.6). Separating real and
imaginary parts, we obtain{
ω = c(µ) sin(ωµτ̃ (N∗(µ))),
b(µ) = −c(µ) cos(ωµτ̃ (N∗(µ))).
(3.5.7)
One can notice that if iω is a purely imaginary root of (3.5.6) then so is −iω. A
necessary condition for equation (3.5.6) to have purely imaginary roots is
| c(µ) |>| b(µ) | . (3.5.8)
If no µ ∈ [0, µ) fulfills condition (3.5.8), then the characteristic equation (3.5.6) has
no purely imaginary root. Consequently, from Lemma 3.5.2, all eigenvalues of (3.5.6)
have negative real parts and the steady state N∗(µ) is locally asymptotically stable
for all µ ∈ [0, µ).
We have already checked that b(µ) + c(µ) > 0. Then, for (3.5.8) to hold true, it
is necessary that c(µ) > 0, that is β(µ) < 0. A sufficient condition for (3.5.8) is then
b(µ) < 0, which is equivalent to
δ + β(µ)
+
(
η(µ)
[
δ + β(µ)
]
+ α(µ)
[
1 + µζ(µ)τ̃ ′(N∗ (µ))
])
µτ̃ ′(N∗ (µ))e−γµτ̃(N∗(µ)) < 0.
(3.5.9)
From now on, we assume there exists µ∗ ∈ (0, µ) such that (3.5.8) is fulfilled for
µ ∈ [0, µ∗).
System (3.5.7) is equivalent to
cos(ωµτ∗(µ)) = −b(µ)
c(µ) , sin(ωµτ
∗(µ)) = ω
c(µ) , (3.5.10)
where τ∗ (µ) = τ̃ (N∗(µ)). Therefore adding the squares of both sides of (3.5.10),
purely imaginary eigenvalues iω of (3.5.6), with ω > 0, must satisfy
ω =
(
c2(µ)− b2(µ)
) 1
2 . (3.5.11)
Thus, in the following, we will think of ω as ω(µ), µ ∈ [0, µ∗). Substituting expression
(3.5.11) for ω in (3.5.10), we obtain
cos
(
µτ∗(µ)
(
c2(µ)− b2(µ)
) 1
2
)
= −b(µ)
c(µ) ,
sin
(
µτ∗(µ)
(
c2(µ)− b2(µ)
) 1
2
)
=
(
c2(µ)− b2(µ)
) 1
2
c(µ) .
(3.5.12)
From the above reasoning, values of µ ∈ [0, µ∗) solutions of system (3.5.12) gener-
ate positive ω(µ) given by (3.5.11), and hence yield imaginary eigenvalues of (3.5.6).
Consequently, we look for positive solutions µ of (3.5.12) in the interval [0, µ∗). They
satisfy
µτ∗(µ)
(
c2(µ)− b2(µ)
) 1
2 = arccos
(
−b(µ)
c(µ)
)
+ 2kπ, k ∈ N0,
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where N0 denotes the set of all nonnegative integers. We set
µk(µ) :=
arccos
(
− b(µ)c(µ)
)
+ 2kπ
τ∗(µ) (c2(µ)− b2(µ))
1
2
, k ∈ N0, µ ∈ [0, µ∗).
Values of µ for which ω(µ) =
(
c2(µ)− b2(µ)
) 1
2 is a solution of (3.5.7) are roots of the
functions
Zk(µ) = µ− µk(µ), k ∈ N0, µ ∈ [0, µ∗). (3.5.13)
The roots of Zk can be found using popular software, but are hard to determine with
analytical tools [19]. The following lemma states some straightforward properties of
the Zk functions.
Lemma 3.5.3. For k ∈ N0,
Zk(0) < 0 and lim
µ→µ∗
Zk(µ) = −∞.
Therefore, provided that no root of Zk is a local extremum, the number of positive
roots of Zk, k ∈ N0, on the interval [0, µ∗) is even. Moreover, if Zk has no root on the
interval [0, µ∗), then Zj , with j > k, does not have positive roots.
Remark 1. The last statement in Lemma 3.5.3 implies, in particular, that, if Z0
has no positive root, then (3.5.7) has no positive solution, and equation (3.5.6) does
not have pure imaginary roots.
The search for purely imaginary roots ends up finding positive real roots of real
functions Zk, that can mostly be handled numerically. In the following proposition
however, we establish some properties of purely imaginary roots of equation (3.5.6)
using a method described in [72].
Proposition 3.5.4. Let ±iω(µc), with ω(µc) > 0 and µc ∈ (0, µ∗), be a pair of purely
imaginary roots of equation (3.5.6) when µ = µc. Then ±iω(µc) are simple roots of
(3.5.6) such that
sign
{
dRe(λ(µ))
dµ
}
µ=µc
= sign
{
c3 (µcτ̂ ′c + τ∗c ) + c2c′µcτ∗ − c(b2 (µcτ̂ ′c + τ∗c ) + b′ + bb′µcτ∗c ) + c′b
}
,
(3.5.14)
with τ∗c = τ∗(µc), τ̂ ′c = dτ∗(µc)/dµ, b = b(µc), c = c(µc), b′ = b′(µc) and c′ = c′(µc).
Proof. Let λ(µ) be a family of roots of (3.5.6), so ∆(λ(µ), µ) = 0, such that λ(µc) =
iω(µc). Then,
dλ
dµ
(µ)∆λ(λ, µ) + ∆µ(λ, µ) = 0, (3.5.15)
where
∆λ(λ, µ) :=
d∆
dλ
(λ, µ) = 1− c(µ)µτ∗(µ)e−λµτ∗(µ),
and
∆µ(λ, µ) :=
d∆
dµ
(λ, µ) = b′(µ)− [c(µ)
(
µτ̂ ′(µ) + τ∗(µ)
)
λ− c′(µ)]e−λµτ∗(µ),
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with τ̂ ′(µ) = dτ̃(N∗(µ))/dµ.
Assume, by contradiction, that λ(µc) = iω(µc) is not a simple root of (3.5.6). Then
∆λ(iω(µc), µc) = 1− µcτ∗c c(µc)e−iω(µc)µcτ
∗
c = 0.
Using (3.5.6) for µ = µc, we then deduce b(µc)+1/(µcτ∗c )+iω(µc) = 0, and consequently
ω(µc) = 0, which gives a contradiction. It follows that all purely imaginary roots of
(3.5.6) are simple.
In the following, we do not mention the dependence of the coefficients τ∗, τ̂ ′, b and
c (and their derivatives) with respect of µ.
Since ∆(λ, µ) = 0, we deduce eλµτ∗ = −c/(λ + b). Therefore from (3.5.15) we
obtain (
dλ
dµ
)−1
= c+ cµτ
∗(λ+ b)
[c′ − cλ (µτ̂ ′ + τ∗)] (λ+ b)− b′c .
Taking the real part of the above equality for µ = µc, we obtain
Re
(
dλ
dµ
)−1 ∣∣∣∣
µ=µc
= [c
2(1 + bµcτ∗c ) (µcτ̂ ′c + τ∗c ) + µcτ∗c c(c′ − bc (µcτ̂ ′c + τ∗c ))]ω(µc)2 + c(1 + bµcτ∗c )(c′b− b′c)
(b′c− c′b− c (µcτ̂ ′c + τ∗c )ω(µc)2)
2 + ((c′ − bc (µcτ̂ ′c + τ∗c ))ω(µc)2
.
Notice that sign {dRe(λ)/dµ} = sign{Re (dλ/dµ)−1}. Since iω(µc) is a purely imagi-
nary root of (3.5.5), then, from (3.5.11), ω(µc)2 = c2 − b2, and we obtain
sign
{
dRe(λ)
dµ
∣∣∣∣
µ=µc
}
= sign
{
c[c3 (µcτ̂ ′c + τ∗c ) + c2c′µcτ∗ − c(b2 (µcτ̂ ′c + τ∗c ) + b′ + bb′µcτ∗c ) + c′b]
}
.
As we already noticed, if equation (3.5.5) has pure imaginary roots then necessarily
c > 0. We deduce (3.5.14) and the proof is complete.
We can now state and prove the following theorem dealing with the asymptotic
stability of the positive steady state N∗.
Theorem 3.5.5. Assume (3.5.2) holds true, β and τ are C2 functions. If no µ ∈ [0, µ)
satisfies (3.5.8), then the positive steady state N∗ of (3.5.1) is locally asymptotically
stable for µ ∈ [0, µ).
Assume there exists µ∗ ∈ (0, µ) such that (3.5.8) is fulfilled for µ ∈ [0, µ∗). Then,
the following holds true:
(i) If Z0, defined in (3.5.13), has no root on the interval [0, µ∗), then the positive
steady state N∗ of (3.5.1) is locally asymptotically stable for µ ∈ [0, µ∗).
(ii) If Z0 has at least one positive root µc ∈ (0, µ∗), then N∗ is locally asymptotically
stable for µ ∈ [0, µc), unstable for µ ≥ µc, µ in a neighborhood of µc, and a Hopf
bifurcation occurs at N∗ for µ = µc if
c3 (µcτ̂ ′c + τ∗c ) + c2c′µcτ∗c
−c(b2 (µcτ̂ ′c + τ∗c ) + b′ + bb′µcτ∗c ) + c′b 6= 0.
(3.5.16)
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When (ii) holds true, several stability switch can potentially occur for every τ = τc,
roots of Zk functions.
Proof. From Lemma 3.5.2 we know that N∗ is locally asymptotically stable when
µ = 0. The first statement is straightforwardly satisfied.
Assume there exists µ∗ ∈ (0, µ) such that (3.5.8) is fulfilled for µ ∈ [0, µ∗). If Z0
has no positive root on the interval (0, µ∗), then the characteristic equation (3.5.5) has
no pure imaginary root (see Remark 1 and Lemma 3.5.3). Consequently, the stability
of N∗ cannot be lost when µ increases. We obtain the statement in (i).
Now, if Z0 has at least one positive root, say µc ∈ (0, µ∗), then equation (3.5.5) has a
pair of simple conjugate pure imaginary roots ±iωc for µ = µc. From (3.5.16) together
with Proposition 3.5.4, we have either dRe(λ)/dµ(µ = µc) > 0 or dRe(λ)/dµ(µ =
µc) < 0. By contradiction, we assume there exists a branch of characteristic roots
λ(µ) such that λ(µc) = iωc and dRe(λ(µ))/dµ < 0, for µ < µc, µ close to µc. Then
there exists a characteristic root λ(µ) such that Re(λ(µ)) > 0 and µ < µc. Since N∗ is
locally asymptotically stable when µ = 0, applying Rouché’s Theorem [41], we obtain
that all characteristic roots of (3.5.5) have negative real parts when µ ∈ [0, µc), and
we obtain a contradiction. Thus,
dRe(λ)
dµ
∣∣∣∣
µ=µc
> 0. (3.5.17)
Now, let N be a solution of equation (3.1.16). Then the function x defined, for t ≥ 0,
by
x(t) := N(µt) (3.5.18)
satisfies
ẋ(t) = ζ(µ, xt), (3.5.19)
where ζ : R+ × C → R is given by
ζ(µ, φ) = −µ (δ + β(φ(0)))φ(0) + 2µβ (φ(−τ̃(φ(0))))φ(−τ̃(φ(0)))e
−γµτ̃(φ(0))
1 + 2µτ̃ ′(φ(0))e−γµτ̃(φ(0))β (φ(−τ̃(φ(0))))φ(−τ̃(φ(0)))
,
(3.5.20)
In order to prove the Hopf bifurcation for equation (3.1.16), from the change of
variable in (3.5.18), it suffices to prove the Hopf bifurcation for (3.5.19). In [45],
Eichmann stated some conditions on the function ζ allowing a Hopf bifurcation to
occur at the positive steady state of (3.5.19). The function ζ defined above satisfies in
particular the assumptions in [45], that are not recalled here for the sake of clarity.
The characteristic equation associated with the equilibrium N∗ of (3.5.19) is
∆̃(λ, µ) = λ+ µ
(
δ + β
)
+ µ2α
[
1 + µζτ̃ ′(N∗ (µ))
]
τ ′(N∗ (µ))e−γµτ̃(N∗(µ))
+µ2η
[
δ + β
]
τ ′(N∗ (µ))e−γµτ̃(N∗(µ))
− 2µβ
[
1 + µζτ ′(N∗ (µ))
]
e−γµτ̃(N
∗(µ))e−λµτ̃(N
∗(µ)). (3.5.21)
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Let λ ∈ C. One can see that ∆̃(µλ, µ) = µ∆(λ, µ) for all µ ∈ [0, µ). Then, for
µ ∈ (0, µ), λ is an eigenvalue associated with (3.5.21) if and only if λ/µ is an eigenvalue
associated with (3.5.5). Thus, it is straightforward that (3.5.21) has a unique pair of
simple conjugate purely imaginary eigenvalues for µ = µc, that satisfy (3.5.17), since
these properties hold for the characteristic equation (3.5.5). Then, from [45], a Hopf
bifurcation occurs at N∗ when µ = µc. This concludes the proof.
3.6 Numerical illustrations
We consider β as a Hill function, given by (3.1.2). The following values for the param-
eters are chosen according to [76, 95, 96],
δ = 0.05 day−1, γ = 0.2 day−1, β0 = 1.77 day−1 and r = 3. (3.6.1)
The value of θ is set to θ = 1 cell.g−1, which is not relevant for a quantitative analysis,
but does not modify the qualitative behavior of solutions of (3.1.16).
The delay function τ̃ is chosen as
τ̃(N) = τ̃0 + (τ̃max − τ̃0)
N
N + θτ
,
with τ̃max > τ̃0 > 0 and θτ > 0 (otherwise the delay is constant). Hence τ̃(N), and
consequently τ(N), is an increasing bounded positive function. One may note that
τ0 = µτ̃0 and τmax = µτ̃max.
We use Matlab, and the solver DDESD [105] for state-dependent delay differential
equations, to numerically compute the solutions of (3.1.16).
We choose, for the remaining parameters, the following values
τ̃0 = 0.1 day , τ̃max = 1 day and θτ = 1 cell.g−1. (3.6.2)
With values in (3.6.1) and (3.6.2), a unique positive steady state N∗(µ) of (3.1.16)
exists (condition (3.2.1) holds true) for µ < µ, where computations give µ ≈ 33. We
obtain the functions Zk defined in Lemma 3.5.3. The function Z0 has two roots in
(0, µ∗), µ1 = 3.72 and µ2 = 5.92, and the function Z1 has no roots.
3.6.1 Discussion
The main result of this chapter is Theorem 3.5.5 describing the occurrence of periodic
solutions, in our model, trough a Hopf bifurcation. This is illustrated in Figure 3.1
where we see that the solutions of (3.1.16) periodically oscillate when µ = µ1 with a
period of about 20 days. Variations of the delay function τ̃(N(t)) are also displayed.
The same periodic behavior is observed.
Periodic solutions can be linked to some periodic hematological disorders that are
characterized by significant oscillations of circulating blood cells count with periods
ranging from weeks (19 to 21 days in case of cyclical neutropenia [59]) to several months
(30 to 100 days in case of chronic myelogenous leukemia [59]). Periodic hematological
disorders are of great interest and may offer an undisputed opportunity to better
understand some yet unknown hematopoiesis mechanisms. Our numerical simulations
suggest that our model could be applied to some cases of cyclical neutropenia.
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Figure 3.1: Top: Periodic Solution at the Hopf Bifurcation. With parameters given
by (3.6.1) and (3.6.2) the solution of (3.1.16) undergoes a Hopf bifurcation when µ =
3.72, thus periodic solutions are observed. Bottom: The corresponding delay function
τ̃(N(t)).
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Chapter 4
Interactions between immune chal-
lenges and cancer cells proliferation:
timing does matter! ∗
Abstract
The immune system is a key component of malignant cells control and it is also in-
volved in the elimination of pathogens that threaten the host. Despite our body is
permanently exposed to a myriad of pathogens, the interference of such infections
with the immune responses against cancer has been poorly investigated. Through a
mathematical model, we show that the frequency, the duration and the action (positive
or negative) of immune challenges may significantly impact tumor proliferation. First,
we observe that a long immunosuppressive challenge increases accumulation of cancer-
ous cells only if it occurs 14 years after the beginning of immunosenescence. However,
short immune challenges result in an even greater accumulation of cancerous cells for
the same total duration of immunosuppression. Finally, we show that short challenges
of immune activation could lead to a slightly decrease in cancerous cell accumulation
compared to a long one. Our results predict that frequent and acute immune challenges
could have a different and in some extent higher impact on cancer risk than persistent
ones even they have been much less studied in cancer epidemiology. These results are
discussed regarding the existing empirical evidences and we suggest potential novel
indirect role of infectious diseases on cancer incidence which should be investigated to
improve prevention strategies against cancer.
∗C. Jacqueline, Y. Bourfia, H. Hbid, G. Sorci, F. Thomas, and B. Roche, Interactions between
immune challenges and cancer cells proliferation: timing does matter!, EMPH (2016) : eow025
doi:10.1093/emph/eow025 First published online: August 17, 2016.
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4.1 Introduction
While cancer remains one of the main causes of death in Western countries [47], its
burden is increasing in low-and middle-income countries [80]. Today, the most com-
mon approach for removing cancer cells is to treat affected individuals through surgery,
cytotoxic drugs, and/or radiotherapy [14]. Nevertheless, immunotherapy [87], aiming
to stimulate the immune system to improve the control of cancerous cell proliferation
[89], holds promise to be an alternative of current classic therapies.
In fact, the immune system has three major roles in cancer suppression [103, 115].
First, it can eliminate oncogenic pathogens (i.e. infectious organisms recognized to
have a contribution to carcinogenesis [121]) and therefore protect the host from de-
veloping the associated tumor. Second, it can prevent pro-tumoral inflammatory en-
vironment by resolving inflammation right after pathogen elimination [104]. Finally,
immunosurveillance bring into play many cells both from innate and adaptive immu-
nity, especially T cells [115], that eliminate tumor cells and produce signaling molecules
(cytokines) at both the tumor and peripheral sites [75].
However, it is now well recognized that immune system fails to avoid cancer prolifer-
ation and can have a paradoxical role which has been explained by the immunoediting
hypothesis [39]. At some point, immune clearance is switched to escape mechanisms,
such as recruitment of immunosuppressive cells, allowing an increase in cancerous cell
accumulation in late cancer stage [42]. Immune cells can also promote angiogenesis,
produce growth factors and increase chronic inflammation in the tumor microenviron-
ment which are considered as hallmarks of cancer and could result in activation of
premalignant lesions[39, 52].
Humans are probably exposed to a high number of immune challenges (through con-
tact, ingestion and inhalation) [17] which could impact the roles of the immune system
in carcinogenesis. Especially, our immune system is implicated in control/elimination
of intra- and extra-cellular infectious agents through a complex network of interdepen-
dent immune pathways that also involves adaptive immunity against cancerous cells
control [48]. However, the role of immune challenges following infections, which could
divert adaptive immunity against cancerous cells, has been poorly investigated.
First, infections could have a detrimental role for the host by reducing immune
responses against cancerous cells. In fact, they can induce immunosuppression, here
defined as a decrease in efficiency of innate and adaptive actors (due to depletion of
dividing cells for instance). HIV infection is one of the most well-known examples of
an immunosuppressive virus as it depletes CD4+ T cells [25]. These CD4 helper T cells
produce high level of IFN-γ, as well as chemokines, that enhance the priming and ex-
pansion of CD8 cytotoxic cells which eliminate cancerous cells [68]. Helminths species
are also able to impair immune efficiency through their immunoregulatory roles [82].
In fact, helminths are known to inhibit T cell proliferation and to promote expansion
of Treg cells which are able to impede effective immunity against cancer by secreting
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TGF-β [68].
Second, infections are known to induce adaptive immune responses that could boost
the elimination of cancerous cells. Early after an infection, the quantity of humoral
and cellular effectors increases during acute inflammation and could cross react with
tumoral antigens [88, 113]. In addition, the well-known trade-off between the Thl/Thl7
and Th2 immune pathways suggests that Thl or Th2 cytokines are able to downreg-
ulate each other and the associated humoral and cellular effectors [67]. However, Thl
activation is associated with protection against some cancers [54, 64]. In fact, it results
in recruitment of natural killer (NK) cells and type I macrophages to tumor sites, which
can act in concert toward tumor control [91]. Thus, all the infections that activate Thl
could reduce cancerous cell accumulation.
The timing of these immune challenges may also be crucial since our immune system
is not permanently fully efficient. Indeed, immunosenescence is a process that reflects
a gradual decrease of immune system activity with age mainly through a decreased
capacity of immunosurveillance [49]. The beginning of immunosenescence is assumed
to be associated with the beginning of thymopoiesis decline. Indeed, the thymusplay
a crucial role in the development of T cells but also in maintaining immune efficiency
[102]. Maximal activity is reached at puberty (from 10 to 19 years old according to the
World Health Organization) and decrease progressively in adults [108]. The elderly
(> 65 years old; WHO) usually have the following: (i) a depleted population of naive
T cells (the set of T lymphocytes that can respond to novel antigens) [92, 93], (ii) a
shrinking repertoire of T cell clones [55, 83, 93], (iii) an increased number of natu-
rally occurring regulatory T cells that down-regulate T cell responses [46, 98], (iv) a
low grade, pro-inflammatory status [92], and (v) increased numbers of myeloid-derived
suppressor cells, which are associated with impaired T-cell functioning and produce
high amounts of reactive oxygen species [24]. All these immune-associated changes can
potentially promote tumor proliferation [55].
While the role of immunosenescence on cancer development has already been sug-
gested [93], the combination of this long-term irreversible process with sporadic, tran-
sient immune challenges has rarely been considered. In this article, we explore theoret-
ically the combined role of immunosenescence with both persistent and repeated acute
immune challenges on proliferation of cancerous cells. To this purpose, we consider
that challenges could reduce or boost immune responses against cancerous cells. We
also discuss the potential consequences of our findings in terms of cancer prevention.
4.2 Materials and Methods
We explored the combined influence of immunosenescence with sporadic and partial al-
teration of immune system functioning on the accumulation of cancerous cells through
the following theoretical framework:
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where H represents healthy cells, P precancerous cells, C cancerous cells, and I can-
cerous cells that are invisible to the immune system. In a sequential manner, healthy
cells become precancerous at rate µ1 which represent (precancerous cells meet the
following criteria: (i) they increase the risk of cancer; (ii) cancerous cells arise from
precancerous cells and (iii) precancerous cells are different from cancerous cells and
normal cells but share some of their molecular and phenotypic properties [20]. Then,
precancerous cells become cancerous at rate µ2, and finally invisible at rate µ3. We
consider that invisible cancerous cells have acquired the capacity to avoid destruction
by immune system whatever the mechanism implied (e.g. loss of MHC molecules and
secretion of cytokines). Healthy and precancerous cells replicate at rate β1 while can-
cerous and invisible cells replicate at rate β2 (greater than β1) with a maximal total
number of cells K (i.e. carrying capacity) in order to induce competition between
different kinds of cells. We assumed that cancerous cells (C and I) are autonomous
and do not depend of precancerous cells to survive. Such assumption could have an
impact only if precancerous cells disappeared from the population, which is unlikely to
occur with our parameters chosen in accordance with the available literature (Figure
4.1).
Each precancerous and cancerous cells can be eliminated from the organism through
the function ω(t). This function, temporally forced, aims to mimic the efficiency of the
immune system during the lifetime of the organism considered. Five main parameters
describe this function:
ω(t) = a1, if t < b0,
ω(t) = a1 − a2t, if t > b0,
ω(t) = (a1 − a2t)a3, if cn > t > dn,
with ω(t) < a1
where a1 represents the immune system efficiency before the beginning of im-
munosenescence (occurring at time b0). When immunosenescence starts, we assume
that the immune system’s efficiency decreases linearly with time through a coefficient
a2. As the number of immune challenges encountered in one life is particularly hard
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Figure 4.1: Parameters values chosen in accordance with the available literature.
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to determine, we choose a restrictive number of 30 challenges from ages 20 to 80 years.
During an immune challenge n (starting at time cn and ending at time dn, thus for a
duration dn − cn), the immune system efficiency is multiplied by a proportion a3 that
characterizes the amplitude and the direction of this immune system alteration (with
−1 < a3 < 1; allowing a gradual efficiency from immunosuppression when 0 < a3 < 1
with a positive impact on cancerous cells proliferation to a negative impact through
immune system activation when −1 < a3 < 0). We assume that these immune chal-
lenges occur evenly between the beginning of immunosenescence and the end of life.
In other words, the duration between each challenge will be identical. This flexible
function allows us to study different scenarios of temporary and partial alteration of
the immune efficiency which few of them are illustrated in Figure 4.2. While our the-
oretical framework can address a gradient in the duration of immune challenges, we
consider that an acute immune challenge lasts for < 6 months whereas persistent ones
alter immune system for a longer period of time.
Figure 4.2: Examples of different immune system activity across ages (0 to 80).
We explore the respective contribution of the duration and the frequency of immune
challenges on the number of cancerous cells at the age of 80 (assumed to be the end
of individual’s life), used as an estimation of cancer risk. We start all our simulations
by considering that individuals have only healthy cells (S = K, P = 0; C = 0; I
= 0). Finally, we test for the sensitivity of these impacts through a Latin Hypercube
Sampling [62] with 100 iterations that allows exploring the robustness of our conclusion
by adding uncertainties around parameters values.
4.3 Results
Influence of timing and duration of a single immunosuppressive challenge
We first aimed to quantify the influence of the duration and timing of a single im-
munosuppressive challenge on cancerous cell accumulation at the end of individual
life. Figure 4.3 shows that a long episode of immunosuppression leads to large accu-
mulations of non-healthy cells by avoiding their elimination by the immune system.
Our theoretical framework also shows that the timing of the challenge through
the lifespan is worth of consideration. In fact, Figure 4.3 highlights that a persistent
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immunosuppressive challenge occuring before immunosenescence will not significantly
impact cancerous cell accumulation even if it persists during 40 years. To have a sig-
nificant increase of nonhealthy cells at the age of 80 years, the challenge must occur
at least 14 years after the beginning of immunosenescence. Since the immune system
is weaker at this time than before immunosenescence, numerous cancerous invisible
cells may have emerged during the immunosuppressive challenge, yielding a continu-
ous proliferation of these cells, even when the individual recovers. In addition, even if
the immunosuppressive challenge occurs 25 years after the beginning of immunosenes-
cence, it will have an impact on cancerous cell accumulation only if it persists 29 years.
Figure 4.3: Contour plot of the number of cancerous cells at 80 (ranging from dark
blue for accumulation of less than 500 cancer cells to dark red for situations with more
than 3000 cells) according to the date of an immunosuppressive infection after the
beginning of immunosenescence and its duration. The maximal number of cancerous
cells accumulates for 20 challenges with a total duration of 40 years (i.e., 3311 cells).
Parameters are detailed in Figure 4.1
Combined effect of duration and the number of immunosuppressive chal-
lenges
We then explored the combined influence of the duration and number of immunosup-
pressive challenges on cancerous cell accumulation. As previously said, we assumed
that challenges are evenly distributed after the beginning of immunosenescence.
First, we observe that several short immune challenges could lead to larger accu-
mulation of nonhealthy cells than a long episode lasting for the same total duration
of immunosuppression (quantified by the product between number of immunosuppres-
sive challenges and their duration) (Figure 4.4). The positive relation between total
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immunosuppression and number of cancerous cells accumulated (Figure 4.4 Inplot)
suggests that the role of acute challenges is worthy of consideration.
Figure 4.4: Influence of the number of immunosuppressive infections and their dura-
tion on the accumulation of cancerous cells (range from dark blue for accumulation of
less than 500 cancer cells to dark red of more than 2500 cells) . White area represents
parameters sets where total immunosuppression period is greater than 60 years. The
maximal number of cancerous cells accumulated at 80 is of 2653 cells. (Inplot) Re-
lationship between total immunosuppression duration and accumulation of cancerous
cells. Parameters are detailed in Figure 4.1. cn and dn are modified along axes.
Then, to confirm this observation, we explored two different scenarios where chal-
lenges can be persistent or acute and evenly repeated 30 times. We found that a single
long immunosuppression challenge leads to a very small change in cancerous cells ac-
cumulation while 30 repeated short challenges covering the same total duration are
expected to produce a sharper increase in the proliferation of cancerous cells (Figure
4.5). These conclusions are robust to sensitivity analysis and also hold when partial
immunosuppression of weaker amplitude is considered (see Supplementary Fig. S1 in
Appendix A).
Influence of immune activation challenges combined with immunosenes-
cence
Noticing the significant effect of repeated immunosuppressive challenges on accumula-
tion of cancerous cells, we then looked at the influence of immune activation challenges
on the same estimation of cancer risk. With our realistic parameters, we found that a
long period of immune activation slightly reduce the number of cancerous cells (Sup-
plementary Fig. S2 in Appendix A). In addition, 30 repeated immune stimulations
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Figure 4.5: Influence of the number of immunosuppressive infections on the accumu-
lation of cancerous cells. For a total immunosuppression duration indicated on x-axis
(in years), red area shows that a single immunosuppressive infection has almost no
influence of number of cancerous cells at the end of individual life. On the oppo-
site, blue area shows the sharp increase in this abundance of cancerous cells when
immunosuppression is distributed over 30 short infections. The maximal accumulation
of cancerous cells for 30 challenges and a total duration of 7.5 years is of 370 cells.
Parameters are detailed in Figure 4.1. Areas are confidence intervals quantified by a
Latin Hypercube Sampling (LHS) with 100 iterations allowing testing sensitivity for a
5% change in all parameter values and solid lines represent the median value obtained
from LHS.
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lead to a higher decrease of cancerous cells than a single long one for the same to-
tal duration (Figure 4.6 and Supplementary Fig. S3 in Appendix A), but with weak
amplitude. Since we assume that immune system efficiency cannot be higher than
before immunosenescence, the net increase of immune system activation cannot be of
the same magnitude than negative effects (e.g. an increase of 70% could result in a
"net" increase much lower because the maximal activity is constrained by the immune
system efficiency before immunosenescence beginning, as shown in Figure 4.2).
Figure 4.6: Influence of the number of immune activation following infections on the
accumulation of cancerous cells. For a total immune activation duration indicated on
x-axis (in years), red area shows that a single infection has almost no influence of
number of cancerous cells at the end of individual life. Blue area shows the slight
decrease in this abundance of cancerous cells when immune activation is distributed
over 30 short infections. The minimal accumulation of cancerous cells for 30 challenges
and a total duration of 7.5 years is of 305 cells. Parameters are detailed in Figure 4.1.
Areas are confidence intervals quantified by a Latin Hypercube Sampling (LHS) with
100 iterations allowing testing sensitivity for a 5% change in all parameter values and
solid lines represent the median value obtained from LHS.
4.4 Discussion
Our model describes the paradoxical role of immune challenges on cancer risk with a
particular emphasis on the neglected role of acute challenges (i.e. alteration of immune
efficiency for less than 6 months). These immune challenges can be beneficial for can-
cerous cell proliferation when they downregulate the adaptive tive immune response
to cancer (called immunosuppressive challenges) or detrimental to cancerous cell pro-
liferation when they upregulate this immune pathway (immune activation challenges).
First, our model predicts that repeated acute immunosuppressive challenges may in-
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crease cancer proliferation in a greater extent than a persistent one for the same total
immunosuppression duration. Frequent immunosuppressive episodes, combined with
immunosenescence, may result in the immune system’s failure in controlling cancer
cells growth and density, due to immunosuppressive episodes occuring prior to the re-
covery of maximal elimination of cancerous cells. In contrast, repeated short immune
activation episodes could slightly reduce the accumulation of cancerous cells compared
to a single persistent challenge. Regular activation of the immune system could offset
the action of immunosenescence and therefore may offer a protection regarding age-
related cancerous cell accumulation.
As for any modeling approach, our model is based on a series of simplifying as-
sumptions that deserved to be discussed. First of all, as dynamics and cross-talk with
the immune system could be different for congenital and acquired cancer, further stud-
ies need to assess the influence of immune challenges on cancerous cell accumulation
for each of them. Then, we assumed that the immune system removes cancerous and
precancerous cells in an identical manner, whatever their phenotype. This should be
relaxed in future studies regarding the huge diversity of cancerous and precancerous
cells [120], which suggests that immune effectors can specifically target only some can-
cerous clones. Third, we made the hypothesis that immunosenescence follows a purely
gradual process, while it is possible that nonlinear relationships exist between age and
immune function, especially in the very elderly [119]. To take into account this issue,
we tested different immunosenescence curve shapes but they do not significantly change
our results (Supplementary Fig. S4 in Appendix A). The parameter values chosen in
this study may influence the quantitative outcomes of our theoretical framework, but
we would like to point out that our conclusions are robust to changes in the parameter
space (as shown in Supplementary Data, see in Appendix A).
While more realistic and complex models can be compared with empirical data,
we nevertheless believe that our simple and general model can nevertheless provide a
number of testable predictions on how immune challenges may affect the risk of ma-
lignancy via the immune system. Indeed, a lot of uncertainties are documented on
what could be the impact of each component of the immune system on cancerous cell
proliferation [52]. Therefore, a model with a greater complexity will have to deal with
a lot of speculation about each of these components, decreasing its relevance to study
transient immune challenges over cancer progression. While this should be a natu-
ral next step of our research work, it was then important highlighting this possibility
through a simple model.
The originality of our study is to predict that acute immunosuppressive infections
could also impact cancer risk and in a larger extent than persistent infections. Em-
pirical evidences of such situation are obviously harder to identify, but the impact of
"common" diseases on immune system and their relation with cancer risk are worthy of
investigation. In fact, a protein secreted by influenza A virus (pandemic flu) inhibits
IFNβ expression and therefore suppresses both innate and acquired immune responses
[60]. In addition, other common viruses as rhinovirus, responsive of common cold and
rotavirus, agent of gastroenteritis, have also been associated with a immune deficiency
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in infected people [69, 97]. As individuals may experience several episodes of flu, com-
mon cold and gastroenteritis during their course of life, these numerous short induced
immunosuppression periods will probably not be neutral concerning the accumulation
of cancerous cells. However, history of common colds or gastroenteritis prior to cancer
diagnostic has been associated with a decreased cancer risk in a cohort study [1]. It
may suggest that infections have a complex impact on immune responses to cancer
and that further studies need to consider the temporal dynamic of immune challenges
following the entry of an infectious organism. Finally, a complete and persistent im-
munosuppression following infections seems unlikely and latent infections (EBV and
Herpesvirus) could rather produce short immunosuppression challenges each time they
reactivate.
Conversely, our results suggest that multiple immune activations across life could
decrease cancer risk comparing to a single one. The discontinuity theory proposed
by Pradeu and colleagues [94] could give an explanation to this result. The theory
states that immune responses are induced by the appearance of molecular motifs that
are different from those with which the immune system has regularly interacted so far
and could be tolerant regarding to motifs that are persistent. As a matter of fact,
apparent protection against lung cancer has been observed in humans frequently ex-
posed to cattle in the dairy industry [85]. It is possible that this protection is provided
by endotoxins present in the dust which are known to be potent immune stimulating
factors [100]. Moreover, evidences of acute infections being antagonistic to cancer has
been reviewed by [37].
We do believe that this study could be the first step to envision innovative guide-
lines for cancer prevention and identification of groups at risk for cancer. Impacts of
immunechallenges are particularly worth of interest to study the observed disparity
of cancer incidences between low and high-income countries. Our results suggest a
stronger impact of acute and repeated immune challenges after the beginning of im-
munosencence. This situation could be applied to high-income countries where longer
lifespan have been shown to induce chronic low-grade inflammation, contributing to
immune disorders in older individuals [114]. Even if poor-quality of available data
and the comparatively shorter life expectancy may explain lower cancer incidence in
low-income countries [27], we suggest that it could also be linked to the frequency and
the nature of immune challenges (numerous short periods of immune activation). It
may also depend on variability of individuals immune system (see Supplementary Fig.
S5). In fact, it has been shown that variation in the human immune system is largely
driven by nonheritable influences [29]. Depending on their environment, individuals
will: (i) have different quantity of energy available to invest in their immune responses
and (ii) meet different infectious burden and thus different levels of selective pressure
to develop a fully efficient immune system [66]. In addition, antigenic exposure early
in life through common infections is recognized to be essential for establishing an im-
munological memory [65]. All these sources of variation may impact the frequency and
the time of infection but they could also directly impact the probability to develop
cancer.
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Finally, exploring the consequences of frequent immune challenges could become an
interesting alternative way to design more integrative public health strategies, moreover
regarding the issue of chemotherapy resistance that puzzles the scientific community
since decades and the development of immunotherapy strategies.
Conclusion and Perspectives
In the first part of this thesis, by proposing and analyzing two mathematical models
describing healthy hematopoietic stem cells dynamics, we aimed to reach two distinct
but all too important objectives. From a mathematical stand point, we aspired to con-
tribute to the study of age-structured models and the theory of differential equations
with distributed delay as well as those with state dependent delay. From a biological
stand point, we aspired to emphasize the influence of some factors and/or parameters,
related to hematopoietic stem cells dynamics such as growth factors, differentiation,
proliferation, cell cycle duration and apoptosis, on blood cells behavior and count in
the bloodstream.
The second part of this thesis focused on cancerous cells dynamics and their in-
teractions with immune system responses. Where we argued that frequent and acute
immune challenges could have a different and, in some extent, higher impact on cancer
risk than persistent ones. These results allowed us to suggest a potential novel indi-
rect role of infectious diseases on cancer incidence which should be subject to future
investigations in order to improve prevention strategies against cancer. The fact that
these novel, and important, results emerged from a rather simple Ordinary Differential
Equations model encourages us to continue down this path by proposing other "more
mathematically challenging" models that might help us refine our biological results.
The main reason we have used mathematical models and computer simulations,
to describe stem cell dynamics, is their keen ability to predict biological systems and
their behavior that would be difficult to conduct experimentally or formulated through
statistical data alone. Indeed, lab experiments can be costly, time consuming and sub-
ject to biological variation through constantly changing external conditions, whereas
mathematical and numerical models are able to give many answers, to possibly not yet
known scenarios, since complex biological dynamics are reduced to key mechanisms
which enables a more robust analysis of the way the system changes if any of these
mechanisms are interrupted.
Moreover, mathematical models and computational approaches have a rather un-
tapped potential in biomedical research, which has not yet reached full acceptance
by experimentalists and clinicians in many laboratories. We do hope that this thesis
would contribute to convince of the importance to incorporate a dialog between biolo-
gists, clinicians and mathematicians in order to use mathematical models as predictive
tools in future research. We do also believe that such interdisciplinary effort, if carried
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out on a more regular basis, would eventually lead to some invaluable insights that
can be translated into the clinic to ultimately benefit patients.
Appendix A
Supplementary data to Chapter 4
63
Supplementary	materials	
Impact	of	weaker	immunosuppression	amplitude	
	 In	 Chapter	 4,	 we	 show	 that	 repeated	 short	 immunosuppressive	 infections	
have	 a	 larger	 impact	 on	 cancerous	 cells	 than	 a	 single	 long	 one.	 Nevertheless,	 we	
assumed	 in	 the	main	text	 that	 immune	system	activity	 is	decreased	by	70%	during	
infections.	Figure	S1	shows	that	an	 infection	decreasing	 immune	system	activity	by	
only	10%	of	its	capacity	leads	to	similar	conclusion,	even	if	the	pattern	is	less	striking.	
	
	
	
	
	
Figure	S1:	Same	figure	than	Figure	4.5,	but	with	an	amplitude	of	immunosuppression	of	10%	
instead	of	70%	(a3=0.1).	
	
	
	
	
	
	
Influence	 of	 immune	 activation	 following	 infections	 on	 the	 accumulation	 of	
cancerous	cells.	
	
Figure	 S2:	 Same	 figure	 than	 Figure	 4.3,	 considering	 an	 immune	 activation	 following	 the	
infection	(a3=-0.7).	
	
	
Figure	 S3:	 Same	 figure	 than	 Figure	 4.4,	 considering	 an	 immune	 activation	 following	 the	
immune	challenge	(a3=-0.7).	
	
	
	
	
	
	
Impact	of	later	immunosenescence	start	
For	 our	 principal	 results,	 immunosenescence	 has	 been	 started	 at	 20	
according	 to	 the	 beginning	 of	 thymic	 output	 reduction	 (Figure	 4.1).	 However	
telomere	length	of	CD4+	T	cells	decline	around	45	years	(See	Aydar et al.).	Figure	S4	
shows	 that	 a	 later	 immunosenescence	 stat	 to	 similar	 conclusions	 for	
immunosuppressive	infection	and	the	greater	accumulation	of	cancerous	cells	in	the	
case	of	30	repeated	acute	infections	is	even	more	striking.	
	
	
Figure	S4:	Same	figure	than	Figure	4.5,	but	here	immunosenescence	starts	at	45	instead	of	
20	(b0=45).	
	
	
Impact	of	initial	strength	of	immune	system	
For	our	principal	results,	we	assumed	that	 immune	system	efficiency	before	
the	 beginning	 of	 immunosenescence	 allows	 the	 elimination	 of	 70%	 of	 cancerous	
cells	(a1,	Figure	4.1).	However,	the	immune	system	of	individual	is	extremely	variable	
depending	 on	 available	 energy	 and	 personal	 history	 of	 infection.	 Figure	 S5	 shows	
that	 a	 weaker	 basal	 immune	 efficiency	 leads	 to	 similar	 conclusions	 for	
immunosuppressive	infection.	
	
Figure	 S5:	 Same	 figure	 than	 Figure	 4.5,	 but	 here	 immune	 efficiency	 before	
immunosenescence	is	of	40%	(a1=0.4).	
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Sujet : Modélisation et Analyse de Modèles en Dynamique
Cellulaire avec Applications à des Problèmes Liés aux Cancers
Résumé : Cette thèse s’insère dans le cadre général de l’étude de la dynamique des popu-
lations. La population prise en compte étant constituée de cellules souches normales et/ou
cancéreuses. Nous proposons et analysons trois modèles mathématiques décrivant la dy-
namique de cellules souches. Le premier modèle proposé est un modèle d’équations aux
dérivées partielles structurées en âge que nous transformons, via la méthode des caractéris-
tiques, en un système d’équations différentielles à retard pour lequel on étudie l’existence
et la stabilité des points d’équilibres. En construisant une fonction de Lyapunov, on dé-
montre que l’équilibre trivial est globalement asymptotiquement stable lorsqu’il est le seul
équilibre du système. En utilisant l’équation caractéristique, nous analysons la stabilité
asymptotique de l’équilibre positif. On effectue, après, des simulations numériques per-
mettant d’illustrer le comportement des états d’équilibres. Dans le deuxième modèle, on
considère que la durée du cycle cellulaire dépend de la population totale de cellules qui-
escentes. La méthode des caractéristiques nous permet de réduire notre modèle structuré
en âge à un système d’équations différentielles avec un retard dépendant de l’état pour
lequel on effectue une analyse détaillée de la stabilité. En construisant une fonction de
Lyapunov-Razumikhin, nous obtenons une condition suffisante pour la stabilité globale
de l’équilibre trivial. On montre qu’un unique point d’équilibre non-trivial peut appa-
raître par l’intermédiaire d’une bifurcation transcritique de l’équilibre trivial. Une analyse
du comportement de l’état d’équilibre positif nous permet de conclure l’existence d’une
bifurcation de Hopf. Nous confirmons, ensuite, les résultas analytiquement obtenus par
des simulations numériques. Pour le troisième et dernier modèle de cette thèse, on pro-
pose un système d’équations différentielles ordinaires décrivant la dynamique de cellules
souches saines et cancéreuses et prenant en compte leurs interactions avec les réponses
immunitaires. Ce modèle nous a permis de souligner l’ampleur de l’impact que peuvent
avoir différentes infections sur la prolifération tumoral que ce soit par le biais de leurs
fréquences, leurs durées ou la façon dont ils agissent sur le système immunitaire.
Mots clés : Dynamique cellulaire; immunosénescence; cancer; équation aux dérivées par-
tielles structurées en âge; équation différentielle à retard; retard dépendant de l’état; fonc-
tion de Lyapunov; bifurcation de Hopf
Subject : Mathematical Modeling in Cellular Dynamics:
Applications to Cancer Research
Abstract : This thesis fits into the general framework of the study of population dynam-
ics. The population particularly considered in this work is comprised of stem cells with
both cases of healthy and cancerous cells being investigated. We propose and analyze three
mathematical models describing stem cells dynamics. The first model is an age-structured
partial differential model that we reduce to a delay differential system using the charac-
teristics method. We investigate the existence and stability of the steady states of the
reduced delay differential system. By constructing a Lyapunov function, the trivial steady
state, describing cell’s dying out, is proven to be globally asymptotically stable when it is
the only equilibrium of the system. The asymptotic stability of the positive steady state,
the most biologically meaningful one, is analyzed using the characteristic equation. We,
then, conduct some numerical simulations to illustrate the behavior of the steady states.
In the second model, the duration of the cell cycle is considered to depend upon the total
population of quiescent cells. The method of characteristics reduces the age-structured
model to a system of differential equations with a state-dependent delay. We perform
a detailed stability analysis of the resulting delay differential system. By constructing a
Lyapunov-Razumikhin function, we obtain a sufficient condition for the global asymptotic
stability of the trivial steady state. It is shown that a unique non-trivial steady state can
appear through a transcritical bifurcation of the trivial steady state. The analysis of the
positive steady state’s behavior concludes to the existence of a Hopf bifurcation and gives
criteria for stability switches. We confirm the analytical results by numerical simulations.
The third and final model, proposed in this thesis, is an ordinary differential equations
model describing healthy and cancerous stem cells dynamics and their interactions with
immune system responses. Through this model, we show that the frequency, the dura-
tion of infections and their action (positive or negative) on immune responses may impact
significantly tumor proliferation.
Keywords : Cell dynamics; immunosenescence; cancer; age-structured partial differen-
tial equation; delay differential equation; state-dependent delay; Lyapunov function; Hopf
bifurcation
